WO2012076430A1 - Triazolopyridine compounds - Google Patents
Triazolopyridine compounds Download PDFInfo
- Publication number
- WO2012076430A1 WO2012076430A1 PCT/EP2011/071685 EP2011071685W WO2012076430A1 WO 2012076430 A1 WO2012076430 A1 WO 2012076430A1 EP 2011071685 W EP2011071685 W EP 2011071685W WO 2012076430 A1 WO2012076430 A1 WO 2012076430A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- pyridin
- triazolo
- pyrazole
- carbonyl
- Prior art date
Links
- 150000008523 triazolopyridines Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 141
- 150000003839 salts Chemical class 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 5
- JOJAUJFFLWQSGY-UHFFFAOYSA-N 2-methylpyrazole-3,4-dicarboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1C(O)=O JOJAUJFFLWQSGY-UHFFFAOYSA-N 0.000 claims description 133
- -1 pyrrolidin-l-yl Chemical group 0.000 claims description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
- 208000035475 disorder Diseases 0.000 claims description 42
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 31
- KAIBPCXFSJMZOZ-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carboxylic acid Chemical compound CN1N=CC(C(=O)N2CCC2)=C1C(O)=O KAIBPCXFSJMZOZ-UHFFFAOYSA-N 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 30
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 28
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- IFXJPVLEINEZCM-UHFFFAOYSA-N 2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxylic acid Chemical compound CN1N=CC(C(=O)N2CCOCC2)=C1C(O)=O IFXJPVLEINEZCM-UHFFFAOYSA-N 0.000 claims description 27
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 27
- 201000000980 schizophrenia Diseases 0.000 claims description 27
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 22
- 208000028017 Psychotic disease Diseases 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 12
- 208000018737 Parkinson disease Diseases 0.000 claims description 12
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 12
- 125000004043 oxo group Chemical group O=* 0.000 claims description 12
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 208000020925 Bipolar disease Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 208000024254 Delusional disease Diseases 0.000 claims description 10
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 10
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 10
- 208000023105 Huntington disease Diseases 0.000 claims description 10
- 208000019022 Mood disease Diseases 0.000 claims description 10
- 208000016285 Movement disease Diseases 0.000 claims description 10
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 10
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 10
- 208000006011 Stroke Diseases 0.000 claims description 10
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 10
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 10
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 10
- 201000004810 Vascular dementia Diseases 0.000 claims description 10
- 208000026345 acute stress disease Diseases 0.000 claims description 10
- 230000019771 cognition Effects 0.000 claims description 10
- 230000007812 deficiency Effects 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 206010013663 drug dependence Diseases 0.000 claims description 10
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 208000019906 panic disease Diseases 0.000 claims description 10
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 10
- 208000020431 spinal cord injury Diseases 0.000 claims description 10
- 208000011117 substance-related disease Diseases 0.000 claims description 10
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 238000011321 prophylaxis Methods 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- XQJZGMDKGYQINF-UHFFFAOYSA-N 2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-amine Chemical compound N1=C2C=C(N)C=CN2N=C1C1=CC=CC=C1 XQJZGMDKGYQINF-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- BJSCWTFSOOOIIM-UHFFFAOYSA-N n-[2-(2-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound COC1=CC=CC=C1C1=NN2C=CC(NC(=O)C=3N(N=CC=3C(=O)N3CCOCC3)C)=CC2=N1 BJSCWTFSOOOIIM-UHFFFAOYSA-N 0.000 claims description 6
- CKSUCDJJRPWNTA-UHFFFAOYSA-N 2-methyl-4-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)-n-(2-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N3CCCC3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N(C1)CC21COC2 CKSUCDJJRPWNTA-UHFFFAOYSA-N 0.000 claims description 5
- STXAOWHZKBHYIC-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-(2-fluoropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=C(F)N=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 STXAOWHZKBHYIC-UHFFFAOYSA-N 0.000 claims description 5
- JLMYMDOIMGVHPF-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-(6-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3N=C(F)C=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 JLMYMDOIMGVHPF-UHFFFAOYSA-N 0.000 claims description 5
- MGTICEKUZOWQOJ-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-[cyclopropyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound N1=C2C=C(NC(=O)C=3N(N=CC=3C(=O)N3CCC3)C)C=CN2N=C1N(C)C1CC1 MGTICEKUZOWQOJ-UHFFFAOYSA-N 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- DOUUAMLQXIBZDW-UHFFFAOYSA-N n-[2-(dimethylamino)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(pyrrolidine-1-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N(C)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCCC1 DOUUAMLQXIBZDW-UHFFFAOYSA-N 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- KSKUAKPLHQCGDM-UHFFFAOYSA-N 3-n-[2-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-4-n,4-n,2-trimethylpyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=C(F)C=CC=2)=C1C(=O)N(C)C KSKUAKPLHQCGDM-UHFFFAOYSA-N 0.000 claims description 4
- AKVBWFQPCBBIAS-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-2-methyl-n-(8-methyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=CC=CC=3)N=C2C(C)=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCC1 AKVBWFQPCBBIAS-UHFFFAOYSA-N 0.000 claims description 4
- IZHHUVHZKJCWMX-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-(3-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound COC1=CC=CC(C2=NN3C=CC(NC(=O)C=4N(N=CC=4C(=O)N4CCC4)C)=CC3=N2)=C1 IZHHUVHZKJCWMX-UHFFFAOYSA-N 0.000 claims description 4
- QUEDGAVIKVSJNI-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-[2-(2-fluoroethoxy)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C(=CC=CC=3)OCCF)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 QUEDGAVIKVSJNI-UHFFFAOYSA-N 0.000 claims description 4
- WGYZCESXWRLNIS-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-[3-(2-fluoroethoxy)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=C(OCCF)C=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 WGYZCESXWRLNIS-UHFFFAOYSA-N 0.000 claims description 4
- ISWIXHDKOLILSX-UHFFFAOYSA-N 4-n-ethyl-4-n,2-dimethyl-3-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)N(C)CC ISWIXHDKOLILSX-UHFFFAOYSA-N 0.000 claims description 4
- YNLYURCKMJQTBP-UHFFFAOYSA-N 7-[[4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carbonyl]amino]-n-(3,3,3-trifluoropropyl)-[1,2,4]triazolo[1,5-a]pyridine-2-carboxamide Chemical compound C1=CN2N=C(C(=O)NCCC(F)(F)F)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 YNLYURCKMJQTBP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- VQAHZGCLUXOBBQ-UHFFFAOYSA-N n-[2-(3-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound COC1=CC=CC(C2=NN3C=CC(NC(=O)C=4N(N=CC=4C(=O)N4CCOCC4)C)=CC3=N2)=C1 VQAHZGCLUXOBBQ-UHFFFAOYSA-N 0.000 claims description 4
- PNXHQBGWYXOQCC-UHFFFAOYSA-N n-[2-[2-(2-fluoroethoxy)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C(=CC=CC=3)OCCF)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 PNXHQBGWYXOQCC-UHFFFAOYSA-N 0.000 claims description 4
- NVOUOERKESIZEB-UHFFFAOYSA-N n-[2-[ethyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N(C)CC)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCOCC1 NVOUOERKESIZEB-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- BGZGUOKOKNXVNF-UHFFFAOYSA-N 4-(3-fluoroazetidine-1-carbonyl)-2-methyl-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N3CCOCC3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CC(F)C1 BGZGUOKOKNXVNF-UHFFFAOYSA-N 0.000 claims description 3
- BGMWCILRDQPISR-UHFFFAOYSA-N 4-(3-fluoroazetidine-1-carbonyl)-2-methyl-n-(2-propan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C(C)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CC(F)C1 BGMWCILRDQPISR-UHFFFAOYSA-N 0.000 claims description 3
- MWTXFKXBBQMSPC-UHFFFAOYSA-N 4-(3-fluoroazetidine-1-carbonyl)-2-methyl-n-(2-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=NC=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CC(F)C1 MWTXFKXBBQMSPC-UHFFFAOYSA-N 0.000 claims description 3
- NGZLWFMYYBGIQI-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-2-methyl-n-(6-methyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound CC1=CN2N=C(C=3C=CC=CC=3)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCC1 NGZLWFMYYBGIQI-UHFFFAOYSA-N 0.000 claims description 3
- TXLQGRXJJKUSQT-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-(2-fluoropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C(=NC=CC=3)F)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 TXLQGRXJJKUSQT-UHFFFAOYSA-N 0.000 claims description 3
- REYBZKYKKAOSSX-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-(2-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound COC1=CC=CC=C1C1=NN2C=CC(NC(=O)C=3N(N=CC=3C(=O)N3CCC3)C)=CC2=N1 REYBZKYKKAOSSX-UHFFFAOYSA-N 0.000 claims description 3
- ULDAHJJMSUQATQ-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-[ethyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(N(C)CC)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCC1 ULDAHJJMSUQATQ-UHFFFAOYSA-N 0.000 claims description 3
- WBQAHAUEUXCGHF-UHFFFAOYSA-N 4-n,4-n-bis(2-methoxyethyl)-2-methyl-3-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)N(CCOC)CCOC WBQAHAUEUXCGHF-UHFFFAOYSA-N 0.000 claims description 3
- MIXHSCDXYCEQEK-UHFFFAOYSA-N 4-n-(2-methoxyethyl)-4-n,2-dimethyl-3-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)N(C)CCOC MIXHSCDXYCEQEK-UHFFFAOYSA-N 0.000 claims description 3
- QSLRITKWOGNVLR-UHFFFAOYSA-N 4-n-cyclopentyl-4-n,2-dimethyl-3-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)N2CCOCC2)=C1C(=O)N(C)C1CCCC1 QSLRITKWOGNVLR-UHFFFAOYSA-N 0.000 claims description 3
- QMSYRGYQJKMMIC-UHFFFAOYSA-N 4-n-ethyl-2-methyl-3-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)NCC QMSYRGYQJKMMIC-UHFFFAOYSA-N 0.000 claims description 3
- HZEZMNDEOZEPBW-UHFFFAOYSA-N 7-[[4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carbonyl]amino]-n,n-dimethyl-[1,2,4]triazolo[1,5-a]pyridine-2-carboxamide Chemical compound C1=CN2N=C(C(=O)N(C)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCC1 HZEZMNDEOZEPBW-UHFFFAOYSA-N 0.000 claims description 3
- SYGRFMTWZUSRSK-UHFFFAOYSA-N 7-[[4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carbonyl]amino]-n-(2-methoxyethyl)-[1,2,4]triazolo[1,5-a]pyridine-2-carboxamide Chemical compound C1=CN2N=C(C(=O)NCCOC)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCC1 SYGRFMTWZUSRSK-UHFFFAOYSA-N 0.000 claims description 3
- QGRJINKAQUPIKV-UHFFFAOYSA-N 7-[[4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carbonyl]amino]-n-ethyl-[1,2,4]triazolo[1,5-a]pyridine-2-carboxamide Chemical compound C1=CN2N=C(C(=O)NCC)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCC1 QGRJINKAQUPIKV-UHFFFAOYSA-N 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- ISRFNFUHCCEWGY-UHFFFAOYSA-N methyl 2-[methyl-[1-methyl-5-[(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carbonyl]amino]acetate Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)N2CCOCC2)=C1C(=O)N(C)CC(=O)OC ISRFNFUHCCEWGY-UHFFFAOYSA-N 0.000 claims description 3
- FMXYCRPLQYLSJM-UHFFFAOYSA-N n-[2-(2-fluoropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C(=NC=CC=3)F)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 FMXYCRPLQYLSJM-UHFFFAOYSA-N 0.000 claims description 3
- JVNZYVMEYKUTLB-UHFFFAOYSA-N n-[2-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(4-methylpiperazine-1-carbonyl)pyrazole-3-carboxamide Chemical compound C1CN(C)CCN1C(=O)C1=C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=C(F)C=CC=2)N(C)N=C1 JVNZYVMEYKUTLB-UHFFFAOYSA-N 0.000 claims description 3
- ZEVGHDCIHPRKSW-UHFFFAOYSA-N n-[2-(3-hydroxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=C(O)C=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 ZEVGHDCIHPRKSW-UHFFFAOYSA-N 0.000 claims description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- LIAPZVRQSGTITJ-HOTGVXAUSA-N 2-methyl-4-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carbonyl]-n-(2-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C([C@]1(OC[C@]2([H])C1)[H])N2C(=O)C=1C=NN(C)C=1C(=O)NC(=CC1=N2)C=CN1N=C2C1=CC=CN=C1 LIAPZVRQSGTITJ-HOTGVXAUSA-N 0.000 claims description 2
- REGGBZPCWSGEMH-UHFFFAOYSA-N 2-methyl-n-(2-propan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-4-(pyrrolidine-1-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C(C)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCCC1 REGGBZPCWSGEMH-UHFFFAOYSA-N 0.000 claims description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- DCJIBDFVLJMVRP-UHFFFAOYSA-N 3-n-[2-[2-fluoroethyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-4-n,4-n,2-trimethylpyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)N(C)CCF)=C1C(=O)N(C)C DCJIBDFVLJMVRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- ADVHHWGLLPGQGC-UHFFFAOYSA-N 4-(3-fluoroazetidine-1-carbonyl)-n-[2-[2-fluoroethyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(N(CCF)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CC(F)C1 ADVHHWGLLPGQGC-UHFFFAOYSA-N 0.000 claims description 2
- XCQNFTGVTQAWMZ-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-2-methyl-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N3CCOCC3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 XCQNFTGVTQAWMZ-UHFFFAOYSA-N 0.000 claims description 2
- WXQPZUPUCAQSCP-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-2-methyl-n-(2-propan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C(C)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCC1 WXQPZUPUCAQSCP-UHFFFAOYSA-N 0.000 claims description 2
- ZHAMTVQSHADZQD-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-2-methyl-n-(2-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N3CCCC3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 ZHAMTVQSHADZQD-UHFFFAOYSA-N 0.000 claims description 2
- LCBYPCOHWFFSOZ-UHFFFAOYSA-N 4-n,4-n,2-trimethyl-3-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)N(C)C LCBYPCOHWFFSOZ-UHFFFAOYSA-N 0.000 claims description 2
- SWYHUBMAHRFNKR-UHFFFAOYSA-N 4-n-cyclopropyl-2-methyl-3-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=CN2N=C(N3CCOCC3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)NC1CC1 SWYHUBMAHRFNKR-UHFFFAOYSA-N 0.000 claims description 2
- FYCFISARXHPUBG-UHFFFAOYSA-N 4-n-cyclopropyl-4-n,2-dimethyl-3-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)N(C)C1CC1 FYCFISARXHPUBG-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- FRPWECGSAGLCLA-UHFFFAOYSA-N methyl 2-[methyl-[1-methyl-5-[(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carbonyl]amino]acetate Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)N(C)CC(=O)OC FRPWECGSAGLCLA-UHFFFAOYSA-N 0.000 claims description 2
- CNEZRUYAOMDHKP-UHFFFAOYSA-N n-[2-(dimethylamino)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N(C)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCOCC1 CNEZRUYAOMDHKP-UHFFFAOYSA-N 0.000 claims description 2
- UNWDCRAGVWZLGQ-UHFFFAOYSA-N n-[2-[2-fluoroethyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N(CCF)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCOCC1 UNWDCRAGVWZLGQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- IDAXELXJYHXDJH-UHFFFAOYSA-N 2-methyl-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-4-(pyrrolidine-1-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=CC=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCCC1 IDAXELXJYHXDJH-UHFFFAOYSA-N 0.000 claims 2
- WKYDPRVAJPXIQB-UHFFFAOYSA-N 2-methyl-4-(morpholine-4-carbonyl)-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N3CCOCC3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 WKYDPRVAJPXIQB-UHFFFAOYSA-N 0.000 claims 1
- ICNQFDNOBQVNNS-UHFFFAOYSA-N 4-(3-fluoroazetidine-1-carbonyl)-2-methyl-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=CC=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CC(F)C1 ICNQFDNOBQVNNS-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 486
- 239000007787 solid Substances 0.000 description 346
- 239000000203 mixture Substances 0.000 description 176
- 239000000243 solution Substances 0.000 description 173
- 235000019439 ethyl acetate Nutrition 0.000 description 164
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 145
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 139
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 133
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 132
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 126
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 124
- 239000002904 solvent Substances 0.000 description 120
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 101
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 86
- 238000006243 chemical reaction Methods 0.000 description 81
- 239000000047 product Substances 0.000 description 74
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 68
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 67
- 235000017557 sodium bicarbonate Nutrition 0.000 description 66
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 65
- 239000007858 starting material Substances 0.000 description 63
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 62
- 238000001914 filtration Methods 0.000 description 54
- 239000000725 suspension Substances 0.000 description 44
- 239000003480 eluent Substances 0.000 description 43
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 40
- 239000000741 silica gel Substances 0.000 description 40
- 229910002027 silica gel Inorganic materials 0.000 description 40
- 229960001866 silicon dioxide Drugs 0.000 description 40
- 239000000377 silicon dioxide Substances 0.000 description 39
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 35
- 239000012044 organic layer Substances 0.000 description 35
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 34
- 235000019341 magnesium sulphate Nutrition 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 239000013058 crude material Substances 0.000 description 33
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 33
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 29
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 28
- 239000012267 brine Substances 0.000 description 27
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 27
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 25
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- 238000004587 chromatography analysis Methods 0.000 description 23
- 238000003818 flash chromatography Methods 0.000 description 23
- 229960004132 diethyl ether Drugs 0.000 description 22
- 239000012299 nitrogen atmosphere Substances 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 230000002829 reductive effect Effects 0.000 description 19
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 17
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 17
- 229910052786 argon Inorganic materials 0.000 description 16
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 14
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- INIPCPYOESSJQP-UHFFFAOYSA-N 4-ethoxycarbonyl-2-methylpyrazole-3-carboxylic acid Chemical compound CCOC(=O)C=1C=NN(C)C=1C(O)=O INIPCPYOESSJQP-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 12
- 229910000024 caesium carbonate Inorganic materials 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 11
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 10
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000012300 argon atmosphere Substances 0.000 description 10
- 239000012876 carrier material Substances 0.000 description 10
- VEBLEROFGPOMPB-UHFFFAOYSA-N n-methylcyclopropanamine Chemical compound CNC1CC1 VEBLEROFGPOMPB-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 9
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- UPPPWUOZCSMDTR-UHFFFAOYSA-N 1-methyl-pyrazole-4-carboxylic acid Chemical compound CN1C=C(C(O)=O)C=N1 UPPPWUOZCSMDTR-UHFFFAOYSA-N 0.000 description 8
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 8
- CFRUPZZQBVFZLD-UHFFFAOYSA-N 5-[[2-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1C(=O)NC1=CC2=NC(C=3C=C(F)C=CC=3)=NN2C=C1 CFRUPZZQBVFZLD-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000007903 gelatin capsule Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 8
- PXFUWRWCKSLCLS-UHFFFAOYSA-N 3-fluoroazetidine;hydron;chloride Chemical compound Cl.FC1CNC1 PXFUWRWCKSLCLS-UHFFFAOYSA-N 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 6
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 6
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 239000003039 volatile agent Substances 0.000 description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- ZVHRSWGYUNHOQN-UHFFFAOYSA-N 4-(dimethylcarbamoyl)-2-methylpyrazole-3-carboxylic acid Chemical compound CN(C)C(=O)C=1C=NN(C)C=1C(O)=O ZVHRSWGYUNHOQN-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 5
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- RTLIKDCNLFBHAB-UHFFFAOYSA-N ethyl 4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carboxylate Chemical compound C1=NN(C)C(C(=O)OCC)=C1C(=O)N1CCC1 RTLIKDCNLFBHAB-UHFFFAOYSA-N 0.000 description 5
- RFCGZPLGJZELOK-UHFFFAOYSA-N fluoromethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCF)C=C1 RFCGZPLGJZELOK-UHFFFAOYSA-N 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- JVHBILBNECDYIY-UHFFFAOYSA-N 2-fluoropyridine-3-carbonyl chloride Chemical compound FC1=NC=CC=C1C(Cl)=O JVHBILBNECDYIY-UHFFFAOYSA-N 0.000 description 4
- KOHBEDRJXKOYHL-UHFFFAOYSA-N 2-methoxy-n-methylethanamine Chemical compound CNCCOC KOHBEDRJXKOYHL-UHFFFAOYSA-N 0.000 description 4
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 4
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 4
- CACUICBSQINPPT-UHFFFAOYSA-N 5-[[2-(2-fluoropyridin-3-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1C(=O)NC1=CC2=NC(C=3C(=NC=CC=3)F)=NN2C=C1 CACUICBSQINPPT-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Chemical class 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- DWIJZRRWTHBJLM-UHFFFAOYSA-N n-[2-(dimethylamino)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-4-(3-fluoroazetidine-1-carbonyl)-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(N(C)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CC(F)C1 DWIJZRRWTHBJLM-UHFFFAOYSA-N 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 3
- NCONOGCFMPPUSQ-UHFFFAOYSA-N 2,7-dibromo-[1,2,4]triazolo[1,5-a]pyridine Chemical compound C1=C(Br)C=CN2N=C(Br)N=C21 NCONOGCFMPPUSQ-UHFFFAOYSA-N 0.000 description 3
- KFHQCRFZHOWKDD-UHFFFAOYSA-N 2-fluoro-n-methylethanamine;hydrochloride Chemical compound Cl.CNCCF KFHQCRFZHOWKDD-UHFFFAOYSA-N 0.000 description 3
- CHEWOEAWPSZAQH-UHFFFAOYSA-N 4-(3-fluoroazetidine-1-carbonyl)-2-methylpyrazole-3-carboxylic acid Chemical compound CN1N=CC(C(=O)N2CC(F)C2)=C1C(O)=O CHEWOEAWPSZAQH-UHFFFAOYSA-N 0.000 description 3
- RAKPSVOTIFMZIA-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-(dimethylamino)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(N(C)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCC1 RAKPSVOTIFMZIA-UHFFFAOYSA-N 0.000 description 3
- RYOCIJISKCZSRO-UHFFFAOYSA-N 4-[2-fluoroethyl(methyl)carbamoyl]-2-methylpyrazole-3-carboxylic acid Chemical compound FCCN(C)C(=O)C=1C=NN(C)C=1C(O)=O RYOCIJISKCZSRO-UHFFFAOYSA-N 0.000 description 3
- UOJKQYPAILNDJF-UHFFFAOYSA-N 4-[2-methoxyethyl(methyl)carbamoyl]-2-methylpyrazole-3-carboxylic acid Chemical compound COCCN(C)C(=O)C=1C=NN(C)C=1C(O)=O UOJKQYPAILNDJF-UHFFFAOYSA-N 0.000 description 3
- NQBVVWZUPHRZJU-UHFFFAOYSA-N 4-[ethyl(methyl)carbamoyl]-2-methylpyrazole-3-carboxylic acid Chemical compound CCN(C)C(=O)C=1C=NN(C)C=1C(O)=O NQBVVWZUPHRZJU-UHFFFAOYSA-N 0.000 description 3
- PQENZNRRKLIARA-UHFFFAOYSA-N 5-[[2-(2-fluoropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1C(=O)NC1=CC2=NC(C=3C=C(F)N=CC=3)=NN2C=C1 PQENZNRRKLIARA-UHFFFAOYSA-N 0.000 description 3
- QKGQWHNXVZBRRR-UHFFFAOYSA-N 5-[[2-(3-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound COC1=CC=CC(C2=NN3C=CC(NC(=O)C=4N(N=CC=4C(O)=O)C)=CC3=N2)=C1 QKGQWHNXVZBRRR-UHFFFAOYSA-N 0.000 description 3
- DEXPUFPXDNTVQY-UHFFFAOYSA-N 5-[[2-(6-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1C(=O)NC1=CC2=NC(C=3N=C(F)C=CC=3)=NN2C=C1 DEXPUFPXDNTVQY-UHFFFAOYSA-N 0.000 description 3
- CQAMQVNXSXHFNH-UHFFFAOYSA-N 5-[[2-[2-fluoroethyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound C1=CN2N=C(N(CCF)C)N=C2C=C1NC(=O)C1=C(C(O)=O)C=NN1C CQAMQVNXSXHFNH-UHFFFAOYSA-N 0.000 description 3
- PAZQSHCXGLBXES-UHFFFAOYSA-N 5-[[2-[cyclopropyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound N1=C2C=C(NC(=O)C=3N(N=CC=3C(O)=O)C)C=CN2N=C1N(C)C1CC1 PAZQSHCXGLBXES-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 101100243082 Caenorhabditis elegans pde-1 gene Proteins 0.000 description 3
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229940123773 Phosphodiesterase 10A inhibitor Drugs 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- CHKQALUEEULCPZ-UHFFFAOYSA-N amino 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S(=O)(=O)ON)C(C)=C1 CHKQALUEEULCPZ-UHFFFAOYSA-N 0.000 description 3
- 229960001040 ammonium chloride Drugs 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229920002678 cellulose Chemical class 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- XWBDWHCCBGMXKG-UHFFFAOYSA-N ethanamine;hydron;chloride Chemical compound Cl.CCN XWBDWHCCBGMXKG-UHFFFAOYSA-N 0.000 description 3
- BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229940057948 magnesium stearate Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- GXSMXRUOAVEHMS-UHFFFAOYSA-N methyl 2-amino-5-fluoropyridine-4-carboxylate Chemical compound COC(=O)C1=CC(N)=NC=C1F GXSMXRUOAVEHMS-UHFFFAOYSA-N 0.000 description 3
- HLTNRIWFYBDWKA-UHFFFAOYSA-N methyl 2-bromo-5-fluoropyridine-4-carboxylate Chemical compound COC(=O)C1=CC(Br)=NC=C1F HLTNRIWFYBDWKA-UHFFFAOYSA-N 0.000 description 3
- UWOZODSMOOALPG-UHFFFAOYSA-N methyl 3-methylpyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1C UWOZODSMOOALPG-UHFFFAOYSA-N 0.000 description 3
- LTEXPORXWFUHGZ-UHFFFAOYSA-N methyl 5-fluoro-2-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-4-carboxylate Chemical compound COC(=O)C1=CC(NC(=O)OC(C)(C)C)=NC=C1F LTEXPORXWFUHGZ-UHFFFAOYSA-N 0.000 description 3
- WZJDOHHMFWJGQW-UHFFFAOYSA-N n,n,1-trimethylpyrazole-4-carboxamide Chemical compound CN(C)C(=O)C=1C=NN(C)C=1 WZJDOHHMFWJGQW-UHFFFAOYSA-N 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 3
- 239000012414 tert-butyl nitrite Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- ZDQCEEUHOCERHC-UHFFFAOYSA-N (1-methylpyrazol-4-yl)-morpholin-4-ylmethanone Chemical compound C1=NN(C)C=C1C(=O)N1CCOCC1 ZDQCEEUHOCERHC-UHFFFAOYSA-N 0.000 description 2
- NARCHHYRFUESTR-UHFFFAOYSA-N 1-methyl-5-[(2-propan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carboxylic acid Chemical compound C1=CN2N=C(C(C)C)N=C2C=C1NC(=O)C1=C(C(O)=O)C=NN1C NARCHHYRFUESTR-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- 150000003930 2-aminopyridines Chemical class 0.000 description 2
- GANCBVCVENSZFN-UHFFFAOYSA-N 2-methyl-4-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)pyrazole-3-carboxylic acid Chemical compound CN1N=CC(C(=O)N2CC3(COC3)C2)=C1C(O)=O GANCBVCVENSZFN-UHFFFAOYSA-N 0.000 description 2
- CYTHALBFRRATMJ-UHFFFAOYSA-N 2-methyl-4-(morpholine-4-carbonyl)-n-(2-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N3CCCC3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 CYTHALBFRRATMJ-UHFFFAOYSA-N 0.000 description 2
- MFCCIDQWIDYOHV-UHFFFAOYSA-N 2-methyl-4-(morpholine-4-carbonyl)-n-[2-(2-oxopyrrolidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N3C(CCC3)=O)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 MFCCIDQWIDYOHV-UHFFFAOYSA-N 0.000 description 2
- KNJUSEKVIYSMOU-UHFFFAOYSA-N 2-methyl-4-(pyrrolidine-1-carbonyl)pyrazole-3-carboxylic acid Chemical compound CN1N=CC(C(=O)N2CCCC2)=C1C(O)=O KNJUSEKVIYSMOU-UHFFFAOYSA-N 0.000 description 2
- QWISSYUYUNTIEP-RNFRBKRXSA-N 2-methyl-4-[(1r,4r)-2-oxa-5-azabicyclo[2.2.1]heptane-5-carbonyl]pyrazole-3-carboxylic acid Chemical compound CN1N=CC(C(=O)N2[C@@H]3C[C@@H](OC3)C2)=C1C(O)=O QWISSYUYUNTIEP-RNFRBKRXSA-N 0.000 description 2
- YDKFYQUWRVMCCE-UHFFFAOYSA-N 2-methyl-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-4-(pyrrolidine-1-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N3CCOCC3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCCC1 YDKFYQUWRVMCCE-UHFFFAOYSA-N 0.000 description 2
- RXBYDYSXIHJXNO-UHFFFAOYSA-N 2-oxa-6-azoniaspiro[3.3]heptane;oxalate Chemical compound OC(=O)C(O)=O.C1NCC11COC1.C1NCC11COC1 RXBYDYSXIHJXNO-UHFFFAOYSA-N 0.000 description 2
- KSXGQRBTBLQJEF-UHFFFAOYSA-N 3-methoxyazetidine;hydrochloride Chemical compound Cl.COC1CNC1 KSXGQRBTBLQJEF-UHFFFAOYSA-N 0.000 description 2
- INUMWWITSITQSB-UHFFFAOYSA-N 4-(3-methoxyazetidine-1-carbonyl)-2-methyl-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1C(OC)CN1C(=O)C1=C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)N(C)N=C1 INUMWWITSITQSB-UHFFFAOYSA-N 0.000 description 2
- REXMTIADIGLPDL-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-2-methyl-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=CC=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 REXMTIADIGLPDL-UHFFFAOYSA-N 0.000 description 2
- XUPXSKZXYSGJCI-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-(2-bromo-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(Br)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 XUPXSKZXYSGJCI-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- XYVYDPDSDRTULL-UHFFFAOYSA-N 4-methoxycarbonyl-2-methylpyrazole-3-carboxylic acid Chemical compound COC(=O)C=1C=NN(C)C=1C(O)=O XYVYDPDSDRTULL-UHFFFAOYSA-N 0.000 description 2
- BIKRHAMOCRXRKE-UHFFFAOYSA-N 4-n,2-dimethyl-3-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)NC BIKRHAMOCRXRKE-UHFFFAOYSA-N 0.000 description 2
- UFTZOLAYGUREBK-UHFFFAOYSA-N 4-n-(2-fluoroethyl)-4-n,2-dimethyl-3-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)N2CCOCC2)=C1C(=O)N(CCF)C UFTZOLAYGUREBK-UHFFFAOYSA-N 0.000 description 2
- TULOWHMHLDHWQH-UHFFFAOYSA-N 5-[(2-bromo-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1C(=O)NC1=CC2=NC(Br)=NN2C=C1 TULOWHMHLDHWQH-UHFFFAOYSA-N 0.000 description 2
- QHWCICYRAQIWKZ-UHFFFAOYSA-N 5-[[2-(2-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound COC1=CC=CC=C1C1=NN2C=CC(NC(=O)C=3N(N=CC=3C(O)=O)C)=CC2=N1 QHWCICYRAQIWKZ-UHFFFAOYSA-N 0.000 description 2
- CVFNPOJCVVVMGQ-UHFFFAOYSA-N 5-[[2-(3-hydroxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1C(=O)NC1=CC2=NC(C=3C=C(O)C=CC=3)=NN2C=C1 CVFNPOJCVVVMGQ-UHFFFAOYSA-N 0.000 description 2
- YYGMEUGJPKGHBP-UHFFFAOYSA-N 5-ethoxycarbonyl-2-methylpyrazole-3-carboxylic acid Chemical compound CCOC(=O)C=1C=C(C(O)=O)N(C)N=1 YYGMEUGJPKGHBP-UHFFFAOYSA-N 0.000 description 2
- RULTYYNTZACCIP-UHFFFAOYSA-N 6-methyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-amine Chemical compound N1=C2C=C(N)C(C)=CN2N=C1C1=CC=CC=C1 RULTYYNTZACCIP-UHFFFAOYSA-N 0.000 description 2
- JLCGSVYUEFMUPI-UHFFFAOYSA-N 6-methyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-7-carboxylic acid Chemical compound N1=C2C=C(C(O)=O)C(C)=CN2N=C1C1=CC=CC=C1 JLCGSVYUEFMUPI-UHFFFAOYSA-N 0.000 description 2
- DAYYXZOMYRSLBX-UHFFFAOYSA-N 7-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=C(Br)C=CN2N=C(N)N=C21 DAYYXZOMYRSLBX-UHFFFAOYSA-N 0.000 description 2
- NDRCEYOBICJMDS-UHFFFAOYSA-N 7-bromo-n-cyclopropyl-n-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound N1=C2C=C(Br)C=CN2N=C1N(C)C1CC1 NDRCEYOBICJMDS-UHFFFAOYSA-N 0.000 description 2
- FDCXBWAAIZJMAK-UHFFFAOYSA-N 7-bromo-n-ethyl-n-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=C(Br)C=CN2N=C(N(C)CC)N=C21 FDCXBWAAIZJMAK-UHFFFAOYSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000004129 EU approved improving agent Substances 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HGQULGDOROIPJN-UHFFFAOYSA-N azetidin-1-ium;chloride Chemical compound Cl.C1CNC1 HGQULGDOROIPJN-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- CHQVQXZFZHACQQ-UHFFFAOYSA-M benzyl(triethyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC1=CC=CC=C1 CHQVQXZFZHACQQ-UHFFFAOYSA-M 0.000 description 2
- 229950005228 bromoform Drugs 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- IEORIWQNVGFZLC-UHFFFAOYSA-N ethyl 1-methyl-5-[(2-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carboxylate Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)N2CCCC2)=C1C(=O)OCC IEORIWQNVGFZLC-UHFFFAOYSA-N 0.000 description 2
- ZZVPFKWOPZSOST-UHFFFAOYSA-N ethyl 5-[[2-[cyclopropyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylate Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)N(C)C2CC2)=C1C(=O)OCC ZZVPFKWOPZSOST-UHFFFAOYSA-N 0.000 description 2
- BGZCUKRAAMLYCS-UHFFFAOYSA-N ethyl 7-[[4-(azetidine-1-carbonyl)-2-methylpyrazole-3-carbonyl]amino]-[1,2,4]triazolo[1,5-a]pyridine-2-carboxylate Chemical compound C1=CN2N=C(C(=O)OCC)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCC1 BGZCUKRAAMLYCS-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- WFWAYUBRLUUGEO-UHFFFAOYSA-N n-(2-methoxyethyl)-n,1-dimethylpyrazole-4-carboxamide Chemical compound COCCN(C)C(=O)C=1C=NN(C)C=1 WFWAYUBRLUUGEO-UHFFFAOYSA-N 0.000 description 2
- KRMZFLRTZAUVPK-UHFFFAOYSA-N n-ethyl-n,1-dimethylpyrazole-4-carboxamide Chemical compound CCN(C)C(=O)C=1C=NN(C)C=1 KRMZFLRTZAUVPK-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- UKODFQOELJFMII-UHFFFAOYSA-N pentamethyldiethylenetriamine Chemical compound CN(C)CCN(C)CCN(C)C UKODFQOELJFMII-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002385 psychotomimetic effect Effects 0.000 description 2
- MVILWLLYYQVYNH-UHFFFAOYSA-N pyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC=N1.NC(=O)C1=CC=CC=N1 MVILWLLYYQVYNH-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- ZFOKPFPITUUCJX-FHAQVOQBSA-N (1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptane;hydrochloride Chemical compound Cl.C1O[C@]2([H])CN[C@@]1([H])C2 ZFOKPFPITUUCJX-FHAQVOQBSA-N 0.000 description 1
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 1
- UFYBTLOLWSABAU-UHFFFAOYSA-N (2-methylpyridin-4-yl)boronic acid Chemical compound CC1=CC(B(O)O)=CC=N1 UFYBTLOLWSABAU-UHFFFAOYSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- MHOVLDXJDIEEMJ-WCCKRBBISA-N (3s)-oxolan-3-amine;hydrochloride Chemical compound Cl.N[C@H]1CCOC1 MHOVLDXJDIEEMJ-WCCKRBBISA-N 0.000 description 1
- REONQWGHSQHTAC-UHFFFAOYSA-N (5-methylpyridin-3-yl)boronic acid Chemical compound CC1=CN=CC(B(O)O)=C1 REONQWGHSQHTAC-UHFFFAOYSA-N 0.000 description 1
- 0 *C(c1c(C(O)=O)[n](*)nc1)=O Chemical compound *C(c1c(C(O)=O)[n](*)nc1)=O 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N 1-[(2s,3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- JTLAIKFGRHDNQM-UHFFFAOYSA-N 1-bromo-2-fluoroethane Chemical compound FCCBr JTLAIKFGRHDNQM-UHFFFAOYSA-N 0.000 description 1
- DWXJHGNMRLEQMZ-UHFFFAOYSA-N 1-methyl-5-[(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carbonyl chloride Chemical compound CN1N=CC(C(Cl)=O)=C1C(=O)NC1=CC2=NC(N3CCOCC3)=NN2C=C1 DWXJHGNMRLEQMZ-UHFFFAOYSA-N 0.000 description 1
- RIPICRVYYNTADT-UHFFFAOYSA-N 1-methyl-5-[(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1C(=O)NC1=CC2=NC(N3CCOCC3)=NN2C=C1 RIPICRVYYNTADT-UHFFFAOYSA-N 0.000 description 1
- SQVAZOYYDSLMQA-UHFFFAOYSA-N 1-methyl-5-[(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carbonyl chloride Chemical compound CN1N=CC(C(Cl)=O)=C1C(=O)NC1=CC2=NC(C=3C=CC=CC=3)=NN2C=C1 SQVAZOYYDSLMQA-UHFFFAOYSA-N 0.000 description 1
- VGILHKDJTKJVKJ-UHFFFAOYSA-N 1-methyl-5-[(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1C(=O)NC1=CC2=NC(C=3C=CC=CC=3)=NN2C=C1 VGILHKDJTKJVKJ-UHFFFAOYSA-N 0.000 description 1
- RQEDXYSIKBHUHT-UHFFFAOYSA-N 1-methyl-5-[(2-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carboxylic acid Chemical compound CN1N=CC(C(O)=O)=C1C(=O)NC1=CC2=NC(N3CCCC3)=NN2C=C1 RQEDXYSIKBHUHT-UHFFFAOYSA-N 0.000 description 1
- XZYJNHZNHGUSNY-UHFFFAOYSA-N 2,2,2-trifluoro-n-methylethanamine Chemical compound CNCC(F)(F)F XZYJNHZNHGUSNY-UHFFFAOYSA-N 0.000 description 1
- CUOWKFXFKFXJEL-UHFFFAOYSA-N 2,2,2-trifluoro-n-methylethanamine;hydrochloride Chemical compound Cl.CNCC(F)(F)F CUOWKFXFKFXJEL-UHFFFAOYSA-N 0.000 description 1
- SXRABVCKJZPTCJ-UHFFFAOYSA-N 2-(2-fluoropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-amine Chemical compound N1=C2C=C(N)C=CN2N=C1C1=CC=NC(F)=C1 SXRABVCKJZPTCJ-UHFFFAOYSA-N 0.000 description 1
- RXWOHFUULDINMC-UHFFFAOYSA-N 2-(3-nitrothiophen-2-yl)acetic acid Chemical compound OC(=O)CC=1SC=CC=1[N+]([O-])=O RXWOHFUULDINMC-UHFFFAOYSA-N 0.000 description 1
- OYXUXHZDSCNQJH-UHFFFAOYSA-N 2-(6-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-amine Chemical compound N1=C2C=C(N)C=CN2N=C1C1=CC=CC(F)=N1 OYXUXHZDSCNQJH-UHFFFAOYSA-N 0.000 description 1
- ZNFIYSZYTAYNPK-UHFFFAOYSA-N 2-(7-amino-[1,2,4]triazolo[1,5-a]pyridin-2-yl)phenol Chemical compound N1=C2C=C(N)C=CN2N=C1C1=CC=CC=C1O ZNFIYSZYTAYNPK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- IDZUUBMVILMMQQ-UHFFFAOYSA-N 2-[methyl-[1-methyl-5-[(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carbonyl]amino]acetic acid Chemical compound CN(C(=O)C=1C=NN(C=1C(NC1=CC=2N(C=C1)N=C(N=2)C1=CC=CC=C1)=O)C)CC(=O)O IDZUUBMVILMMQQ-UHFFFAOYSA-N 0.000 description 1
- VRHKBNFQGHNLIJ-UHFFFAOYSA-N 2-bromo-5-fluoropyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=NC=C1F VRHKBNFQGHNLIJ-UHFFFAOYSA-N 0.000 description 1
- WQELYFJCZLMZRB-UHFFFAOYSA-N 2-bromo-[1,2,4]triazolo[1,5-a]pyridin-7-amine Chemical compound C1=C(N)C=CN2N=C(Br)N=C21 WQELYFJCZLMZRB-UHFFFAOYSA-N 0.000 description 1
- LLLVHTWJGWNRBD-UHFFFAOYSA-N 2-fluoropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1F LLLVHTWJGWNRBD-UHFFFAOYSA-N 0.000 description 1
- BWRHCKQYCOWAAV-UHFFFAOYSA-N 2-fluoropyridine-4-carbonyl chloride Chemical compound FC1=CC(C(Cl)=O)=CC=N1 BWRHCKQYCOWAAV-UHFFFAOYSA-N 0.000 description 1
- IBZKBSXREAQDTO-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)ethanamine Chemical compound COCCNCCOC IBZKBSXREAQDTO-UHFFFAOYSA-N 0.000 description 1
- RZNHSEZOLFEFGB-UHFFFAOYSA-N 2-methoxybenzoyl chloride Chemical compound COC1=CC=CC=C1C(Cl)=O RZNHSEZOLFEFGB-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- DIWBGXOPLCRSFO-UHFFFAOYSA-N 2-methyl-3-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-4-n-propan-2-ylpyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)NC(C)C DIWBGXOPLCRSFO-UHFFFAOYSA-N 0.000 description 1
- VZMXQLBVZPXDQL-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazine-1-carbonyl)pyrazole-3-carboxylic acid Chemical compound C1CN(C)CCN1C(=O)C1=C(C(O)=O)N(C)N=C1 VZMXQLBVZPXDQL-UHFFFAOYSA-N 0.000 description 1
- IJOKELBZLHFDTH-UHFFFAOYSA-N 2-methyl-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-4-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N3CCOCC3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N(C1)CC21COC2 IJOKELBZLHFDTH-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- YJVKSMUGPBJFDA-UHFFFAOYSA-N 2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-amine;hydrochloride Chemical compound Cl.N1=C2C=C(N)C=CN2N=C1N1CCOCC1 YJVKSMUGPBJFDA-UHFFFAOYSA-N 0.000 description 1
- LZUDHUSPNVPRJL-UHFFFAOYSA-N 2-n,2-n-dimethyl-[1,2,4]triazolo[1,5-a]pyridine-2,7-diamine Chemical compound C1=C(N)C=CN2N=C(N(C)C)N=C21 LZUDHUSPNVPRJL-UHFFFAOYSA-N 0.000 description 1
- WILRLPLWZXCRQI-UHFFFAOYSA-N 2-n-cyclopropyl-2-n-methyl-[1,2,4]triazolo[1,5-a]pyridine-2,7-diamine;hydrochloride Chemical compound [Cl-].N1=C2C=C([NH3+])C=CN2N=C1N(C)C1CC1 WILRLPLWZXCRQI-UHFFFAOYSA-N 0.000 description 1
- DIQOUXNTSMWQSA-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1OC2CNC1C2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- QSUIMLNYDUMGRR-UHFFFAOYSA-N 2-propan-2-yl-[1,2,4]triazolo[1,5-a]pyridin-7-amine Chemical compound C1=C(N)C=CN2N=C(C(C)C)N=C21 QSUIMLNYDUMGRR-UHFFFAOYSA-N 0.000 description 1
- UKFDRDBMOUWVHF-UHFFFAOYSA-N 2-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-7-amine Chemical compound N1=C2C=C(N)C=CN2N=C1C1=CC=CN=C1 UKFDRDBMOUWVHF-UHFFFAOYSA-N 0.000 description 1
- CBADLLKMDKPMDO-UHFFFAOYSA-N 2-pyrrolidin-1-yl-[1,2,4]triazolo[1,5-a]pyridin-7-amine Chemical compound N1=C2C=C(N)C=CN2N=C1N1CCCC1 CBADLLKMDKPMDO-UHFFFAOYSA-N 0.000 description 1
- NGZVNONVXYLYQW-UHFFFAOYSA-N 3,3,3-trifluoropropan-1-amine Chemical compound NCCC(F)(F)F NGZVNONVXYLYQW-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SYVNVEGIRVXRQH-UHFFFAOYSA-N 3-fluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1 SYVNVEGIRVXRQH-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- OSMAGAVKVRGYGR-UHFFFAOYSA-N 3-methylpyridine-4-carboxylic acid Chemical compound CC1=CN=CC=C1C(O)=O OSMAGAVKVRGYGR-UHFFFAOYSA-N 0.000 description 1
- YOYMSQRULXQSIR-UHFFFAOYSA-N 4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-2-methylpyrazole-3-carboxylic acid Chemical compound CN1N=CC(C(=O)N2CCS(=O)(=O)CC2)=C1C(O)=O YOYMSQRULXQSIR-UHFFFAOYSA-N 0.000 description 1
- SRLSRYADAZJPGB-UHFFFAOYSA-N 4-(1,4-diazabicyclo[3.2.1]octane-4-carbonyl)-2-methylpyrazole-3-carboxylic acid Chemical compound CN1N=CC(C(=O)N2C3CCN(C3)CC2)=C1C(O)=O SRLSRYADAZJPGB-UHFFFAOYSA-N 0.000 description 1
- YBTRVGICGCGVRN-UHFFFAOYSA-N 4-(3-methoxyazetidine-1-carbonyl)-2-methylpyrazole-3-carboxylic acid Chemical compound C1C(OC)CN1C(=O)C1=C(C(O)=O)N(C)N=C1 YBTRVGICGCGVRN-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JPWXNSJEAQBDKH-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-2-methyl-n-(2-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=NC=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 JPWXNSJEAQBDKH-UHFFFAOYSA-N 0.000 description 1
- FCMOZFUELQKCQQ-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-2-methyl-n-(2-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=CN=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 FCMOZFUELQKCQQ-UHFFFAOYSA-N 0.000 description 1
- IHTFRMHQYZODDP-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-2-methyl-n-[2-(2-methylpyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]pyrazole-3-carboxamide Chemical compound C1=NC(C)=CC(C2=NN3C=CC(NC(=O)C=4N(N=CC=4C(=O)N4CCC4)C)=CC3=N2)=C1 IHTFRMHQYZODDP-UHFFFAOYSA-N 0.000 description 1
- WTLCYARLRQMTAK-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=C(F)C=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 WTLCYARLRQMTAK-UHFFFAOYSA-N 0.000 description 1
- PPUCOPJITZJLRZ-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-[2-fluoroethyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(N(CCF)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCC1 PPUCOPJITZJLRZ-UHFFFAOYSA-N 0.000 description 1
- VHQNXYFHLGRQBU-UHFFFAOYSA-N 4-(azetidine-1-carbonyl)-n-[2-[3-(fluoromethoxy)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=C(OCF)C=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCC1 VHQNXYFHLGRQBU-UHFFFAOYSA-N 0.000 description 1
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- LXUAONTZSZVYOF-UHFFFAOYSA-N 4-bromopyridin-1-ium-1,2-diamine;2,4,6-trimethylbenzenesulfonate Chemical compound NC1=CC(Br)=CC=[N+]1N.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXUAONTZSZVYOF-UHFFFAOYSA-N 0.000 description 1
- MINURGGJJKMQQQ-UHFFFAOYSA-N 4-bromopyrimidin-2-amine Chemical compound NC1=NC=CC(Br)=N1 MINURGGJJKMQQQ-UHFFFAOYSA-N 0.000 description 1
- BZXPLADBSZWDIH-FZSMXKCYSA-N 4-methylbenzenesulfonic acid;(3r)-oxolan-3-amine Chemical compound N[C@@H]1CCOC1.CC1=CC=C(S(O)(=O)=O)C=C1 BZXPLADBSZWDIH-FZSMXKCYSA-N 0.000 description 1
- IARCCDFCBSYPJC-UHFFFAOYSA-N 4-n,2-dimethyl-3-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-4-n-(2,2,2-trifluoroethyl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)N2CCOCC2)=C1C(=O)N(CC(F)(F)F)C IARCCDFCBSYPJC-UHFFFAOYSA-N 0.000 description 1
- ZVGDFLFSVTUKIH-UHFFFAOYSA-N 4-n,2-dimethyl-3-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-4-n-(2,2,2-trifluoroethyl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)N(CC(F)(F)F)C ZVGDFLFSVTUKIH-UHFFFAOYSA-N 0.000 description 1
- JMGSTKYSWXXUFN-UHFFFAOYSA-N 4-n,4-n-diethyl-2-methyl-3-n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)N2CCOCC2)=C1C(=O)N(CC)CC JMGSTKYSWXXUFN-UHFFFAOYSA-N 0.000 description 1
- GCURDSZLYOVLKA-UHFFFAOYSA-N 4-n-(3-methoxypropyl)-2-methyl-3-n-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-3,4-dicarboxamide Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)NCCCOC GCURDSZLYOVLKA-UHFFFAOYSA-N 0.000 description 1
- BVOQFZLOVFZTBR-UHFFFAOYSA-N 5-[[2-(dimethylamino)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylic acid Chemical compound C1=CN2N=C(N(C)C)N=C2C=C1NC(=O)C1=C(C(O)=O)C=NN1C BVOQFZLOVFZTBR-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- AUBHETFYUXEXGU-UHFFFAOYSA-N 5-ethoxycarbonyl-1-methylpyrazole-4-carboxylic acid Chemical compound CCOC(=O)C1=C(C(O)=O)C=NN1C AUBHETFYUXEXGU-UHFFFAOYSA-N 0.000 description 1
- ODKMOWZZSBXTGB-UHFFFAOYSA-N 6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-amine Chemical compound N=1N2C=C(F)C(N)=CC2=NC=1C1=CC=CC=C1 ODKMOWZZSBXTGB-UHFFFAOYSA-N 0.000 description 1
- LWAVYWCTXJKCHG-UHFFFAOYSA-N 6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-7-carboxylic acid Chemical compound N=1N2C=C(F)C(C(=O)O)=CC2=NC=1C1=CC=CC=C1 LWAVYWCTXJKCHG-UHFFFAOYSA-N 0.000 description 1
- AVYDMRAXLHLEJG-UHFFFAOYSA-N 6-fluoropyridine-2-carbonyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=N1 AVYDMRAXLHLEJG-UHFFFAOYSA-N 0.000 description 1
- ZUVIOJYOJROUMD-UHFFFAOYSA-N 7-bromo-2-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound FC1=CC=CC(C2=NN3C=CC(Br)=CC3=N2)=C1 ZUVIOJYOJROUMD-UHFFFAOYSA-N 0.000 description 1
- AVTHMLVHTNGOOU-UHFFFAOYSA-N 7-bromo-2-(3-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridine Chemical compound COC1=CC=CC(C2=NN3C=CC(Br)=CC3=N2)=C1 AVTHMLVHTNGOOU-UHFFFAOYSA-N 0.000 description 1
- VINDHFKEGLBYML-UHFFFAOYSA-N 7-bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound N1=C2C=C(Br)C=CN2N=C1C1=CC=CC=C1 VINDHFKEGLBYML-UHFFFAOYSA-N 0.000 description 1
- JATIVHGFJAULAI-UHFFFAOYSA-N 7-bromo-n,n-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=C(Br)C=CN2N=C(N(C)C)N=C21 JATIVHGFJAULAI-UHFFFAOYSA-N 0.000 description 1
- COQOEQVYWCUQFN-UHFFFAOYSA-N 7-bromo-n-(2-fluoroethyl)-n-methyl-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1=C(Br)C=CN2N=C(N(CCF)C)N=C21 COQOEQVYWCUQFN-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- KBKGOTRCHPQFNS-UHFFFAOYSA-N 8-methyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-amine Chemical compound N1=C2C(C)=C(N)C=CN2N=C1C1=CC=CC=C1 KBKGOTRCHPQFNS-UHFFFAOYSA-N 0.000 description 1
- QBCPTEUHUSDGJM-UHFFFAOYSA-N 8-methyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-7-carboxylic acid Chemical compound N1=C2C(C)=C(C(O)=O)C=CN2N=C1C1=CC=CC=C1 QBCPTEUHUSDGJM-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- CCPBQGBGFBYKQM-UHFFFAOYSA-N CCN(C)C(c1c(C(Nc2cc3nc(-c4cc(O)ccc4)n[n]3cc2)=O)[n](C)nc1)=O Chemical compound CCN(C)C(c1c(C(Nc2cc3nc(-c4cc(O)ccc4)n[n]3cc2)=O)[n](C)nc1)=O CCPBQGBGFBYKQM-UHFFFAOYSA-N 0.000 description 1
- HTCZCSCNCWRCMI-UHFFFAOYSA-N CN(C)C(c1c(C(Nc2cc3nc(-c4ccccc4OC)n[n]3cc2)=O)[n](C)nc1)=O Chemical compound CN(C)C(c1c(C(Nc2cc3nc(-c4ccccc4OC)n[n]3cc2)=O)[n](C)nc1)=O HTCZCSCNCWRCMI-UHFFFAOYSA-N 0.000 description 1
- POFVVHMAZIFHDP-UHFFFAOYSA-N CN(CCO)C(c1c(C(Nc2cc3nc(-c4ccccc4)n[n]3cc2)=O)[n](C)nc1)=O Chemical compound CN(CCO)C(c1c(C(Nc2cc3nc(-c4ccccc4)n[n]3cc2)=O)[n](C)nc1)=O POFVVHMAZIFHDP-UHFFFAOYSA-N 0.000 description 1
- LQZSLIWRYYTMNM-RPXFAVPDSA-N CN/C(/C(Nc1cc2nc(-c3ccccc3)n[n]2cc1)=O)=C(\C=N)/C(N(C)CC(F)(F)F)=O Chemical compound CN/C(/C(Nc1cc2nc(-c3ccccc3)n[n]2cc1)=O)=C(\C=N)/C(N(C)CC(F)(F)F)=O LQZSLIWRYYTMNM-RPXFAVPDSA-N 0.000 description 1
- SBZIGAKJEPQMGU-UHFFFAOYSA-O C[NH2+]C(C(Nc1cc2nc(I)n[n]2cc1)=O)=C(C=N)C(N1CCC1)=O Chemical compound C[NH2+]C(C(Nc1cc2nc(I)n[n]2cc1)=O)=C(C=N)C(N1CCC1)=O SBZIGAKJEPQMGU-UHFFFAOYSA-O 0.000 description 1
- HYZVCRJASQWSBX-UHFFFAOYSA-N C[n]1ncc(C(N2CCC2)=O)c1C(Nc1cc2nc(NCCO)n[n]2cc1)=O Chemical compound C[n]1ncc(C(N2CCC2)=O)c1C(Nc1cc2nc(NCCO)n[n]2cc1)=O HYZVCRJASQWSBX-UHFFFAOYSA-N 0.000 description 1
- MMCSMWHWVGGCGL-UHFFFAOYSA-N C[n]1ncc(C(N2CCOCC2)=O)c1C(Nc1cc2nc(-c3ccccc3)n[n]2cc1)=O Chemical compound C[n]1ncc(C(N2CCOCC2)=O)c1C(Nc1cc2nc(-c3ccccc3)n[n]2cc1)=O MMCSMWHWVGGCGL-UHFFFAOYSA-N 0.000 description 1
- RGHJRIUULKTAFM-WZQAKFLRSA-N Cc1cncc(-c2n[n](ccc(NC(/C(/NC)=C(/C=N)\C(N3CCC3)=O)=O)c3)c3n2)c1 Chemical compound Cc1cncc(-c2n[n](ccc(NC(/C(/NC)=C(/C=N)\C(N3CCC3)=O)=O)c3)c3n2)c1 RGHJRIUULKTAFM-WZQAKFLRSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- YFANXPLAVKUNFH-UHFFFAOYSA-N Nc1cc2nc(-c3cc(F)ccc3)n[n]2cc1 Chemical compound Nc1cc2nc(-c3cc(F)ccc3)n[n]2cc1 YFANXPLAVKUNFH-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Chemical class 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- LNQNBPRWJJTKFT-UHFFFAOYSA-N azetidin-1-yl-(1-methylpyrazol-4-yl)methanone Chemical compound C1=NN(C)C=C1C(=O)N1CCC1 LNQNBPRWJJTKFT-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- UBLYEVLMRSPMOG-UHFFFAOYSA-N cyclopentylmethanamine Chemical compound NCC1CCCC1 UBLYEVLMRSPMOG-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- CRLTUZKJFOBEOB-UHFFFAOYSA-N ethyl 3-methylpyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC=C1C CRLTUZKJFOBEOB-UHFFFAOYSA-N 0.000 description 1
- DPBHBFWGYSYVHS-UHFFFAOYSA-N ethyl 5-[[2-(2-fluoropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylate Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=C(F)N=CC=2)=C1C(=O)OCC DPBHBFWGYSYVHS-UHFFFAOYSA-N 0.000 description 1
- NHVLCCCRJOIINZ-UHFFFAOYSA-N ethyl 5-[[2-(2-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylate Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C(=CC=CC=2)OC)=C1C(=O)OCC NHVLCCCRJOIINZ-UHFFFAOYSA-N 0.000 description 1
- GKOFCWROCSOLLL-UHFFFAOYSA-N ethyl 5-[[2-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylate Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=C(F)C=CC=2)=C1C(=O)OCC GKOFCWROCSOLLL-UHFFFAOYSA-N 0.000 description 1
- JTVROEBNHGJPBS-UHFFFAOYSA-N ethyl 5-[[2-(6-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamoyl]-1-methylpyrazole-4-carboxylate Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2N=C(F)C=CC=2)=C1C(=O)OCC JTVROEBNHGJPBS-UHFFFAOYSA-N 0.000 description 1
- HHGORNIUWLCVPH-UHFFFAOYSA-N ethyl 7-[(2-methylpropan-2-yl)oxycarbonylamino]-[1,2,4]triazolo[1,5-a]pyridine-2-carboxylate Chemical compound C1=C(NC(=O)OC(C)(C)C)C=CN2N=C(C(=O)OCC)N=C21 HHGORNIUWLCVPH-UHFFFAOYSA-N 0.000 description 1
- JDMSSSKVEUKGFT-UHFFFAOYSA-N ethyl n-[(4-bromopyridin-2-yl)carbamothioyl]carbamate Chemical compound CCOC(=O)NC(=S)NC1=CC(Br)=CC=N1 JDMSSSKVEUKGFT-UHFFFAOYSA-N 0.000 description 1
- FQYYIPZPELSLDK-UHFFFAOYSA-N ethyl pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC=N1 FQYYIPZPELSLDK-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000054918 human PDE10A Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- HQZMRJBVCVYVQA-UHFFFAOYSA-N hydron;methyl 2-(methylamino)acetate;chloride Chemical compound Cl.CNCC(=O)OC HQZMRJBVCVYVQA-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Natural products OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- VKHZZEBGUGGKSD-UHFFFAOYSA-N methyl 1,2-diamino-5-fluoropyridin-1-ium-4-carboxylate;2,4,6-trimethylbenzenesulfonate Chemical compound COC(=O)C1=CC(N)=[N+](N)C=C1F.CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 VKHZZEBGUGGKSD-UHFFFAOYSA-N 0.000 description 1
- FKHYRDVFIFJRQJ-UHFFFAOYSA-N methyl 1-methyl-5-[(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamoyl]pyrazole-4-carboxylate Chemical compound C1=NN(C)C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=CC=CC=2)=C1C(=O)OC FKHYRDVFIFJRQJ-UHFFFAOYSA-N 0.000 description 1
- WNJFGDNRYYEFFH-UHFFFAOYSA-N methyl 6-methyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-7-carboxylate Chemical compound N=1N2C=C(C)C(C(=O)OC)=CC2=NC=1C1=CC=CC=C1 WNJFGDNRYYEFFH-UHFFFAOYSA-N 0.000 description 1
- FWKQPBAUTLIAFG-UHFFFAOYSA-N methyl 8-methyl-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine-7-carboxylate Chemical compound N1=C2C(C)=C(C(=O)OC)C=CN2N=C1C1=CC=CC=C1 FWKQPBAUTLIAFG-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- SPWDRSUDPHFGFX-UHFFFAOYSA-N n-(2-bromo-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(Br)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 SPWDRSUDPHFGFX-UHFFFAOYSA-N 0.000 description 1
- RFGNDZATJOSFDZ-UHFFFAOYSA-N n-(2-fluoroethyl)-n,1-dimethylpyrazole-4-carboxamide Chemical compound FCCN(C)C(=O)C=1C=NN(C)C=1 RFGNDZATJOSFDZ-UHFFFAOYSA-N 0.000 description 1
- FCMHDHVEEFXFKK-UHFFFAOYSA-N n-(6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C=1C2=NC(C=3C=CC=CC=3)=NN2C=C(F)C=1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 FCMHDHVEEFXFKK-UHFFFAOYSA-N 0.000 description 1
- UUCJAUQHFXGNMU-UHFFFAOYSA-N n-[2-(2-fluoropyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=C(F)N=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 UUCJAUQHFXGNMU-UHFFFAOYSA-N 0.000 description 1
- YKAPANKWCPNHKY-UHFFFAOYSA-N n-[2-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=C(F)C=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 YKAPANKWCPNHKY-UHFFFAOYSA-N 0.000 description 1
- WYPCJQTZDHVAPS-UHFFFAOYSA-N n-[2-(3-fluorophenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-4-(3-methoxyazetidine-1-carbonyl)-2-methylpyrazole-3-carboxamide Chemical compound C1C(OC)CN1C(=O)C1=C(C(=O)NC2=CC3=NC(=NN3C=C2)C=2C=C(F)C=CC=2)N(C)N=C1 WYPCJQTZDHVAPS-UHFFFAOYSA-N 0.000 description 1
- WLJMKUFNENICSC-UHFFFAOYSA-N n-[2-(6-fluoropyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3N=C(F)C=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 WLJMKUFNENICSC-UHFFFAOYSA-N 0.000 description 1
- AKFHXLWTSBLBAS-UHFFFAOYSA-N n-[2-[2-fluoroethyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(pyrrolidine-1-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(N(CCF)C)N=C2C=C1NC(=O)C(N(N=C1)C)=C1C(=O)N1CCCC1 AKFHXLWTSBLBAS-UHFFFAOYSA-N 0.000 description 1
- LEOATGWNEJVDHO-UHFFFAOYSA-N n-[2-[3-(2-fluoroethoxy)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=C(OCCF)C=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 LEOATGWNEJVDHO-UHFFFAOYSA-N 0.000 description 1
- UPSICAUTXPTPEV-UHFFFAOYSA-N n-[2-[3-(fluoromethoxy)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound C1=CN2N=C(C=3C=C(OCF)C=CC=3)N=C2C=C1NC(=O)C=1N(C)N=CC=1C(=O)N1CCOCC1 UPSICAUTXPTPEV-UHFFFAOYSA-N 0.000 description 1
- XFGWWICSPHTTPU-UHFFFAOYSA-N n-[2-[cyclopropyl(methyl)amino]-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-2-methyl-4-(morpholine-4-carbonyl)pyrazole-3-carboxamide Chemical compound N1=C2C=C(NC(=O)C=3N(N=CC=3C(=O)N3CCOCC3)C)C=CN2N=C1N(C)C1CC1 XFGWWICSPHTTPU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CDELADZXJDHPDV-UHFFFAOYSA-N n-methyl-1-(6-methylpyridin-3-yl)methanamine Chemical compound CNCC1=CC=C(C)N=C1 CDELADZXJDHPDV-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- ZGNYUQSBJCCWGF-UHFFFAOYSA-N oxetan-3-amine;hydrochloride Chemical compound Cl.NC1COC1 ZGNYUQSBJCCWGF-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Chemical class 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000014786 regulation of synaptic transmission Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- FVBBEPGFLHEFBF-UHFFFAOYSA-N tert-butyl n-(2-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamate Chemical compound N1=C2C=C(NC(=O)OC(C)(C)C)C=CN2N=C1N1CCOCC1 FVBBEPGFLHEFBF-UHFFFAOYSA-N 0.000 description 1
- WABIYRSNGGFAEF-UHFFFAOYSA-N tert-butyl n-(2-pyridin-3-yl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamate Chemical compound N1=C2C=C(NC(=O)OC(C)(C)C)C=CN2N=C1C1=CC=CN=C1 WABIYRSNGGFAEF-UHFFFAOYSA-N 0.000 description 1
- KRSYFYRAEUWDAM-UHFFFAOYSA-N tert-butyl n-(6-fluoro-2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)carbamate Chemical compound N=1N2C=C(F)C(NC(=O)OC(C)(C)C)=CC2=NC=1C1=CC=CC=C1 KRSYFYRAEUWDAM-UHFFFAOYSA-N 0.000 description 1
- CJEUADRMMKISOQ-UHFFFAOYSA-N tert-butyl n-[2-(3-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]carbamate Chemical compound COC1=CC=CC(C2=NN3C=CC(NC(=O)OC(C)(C)C)=CC3=N2)=C1 CJEUADRMMKISOQ-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the invention is concerned with novel triazolopyridine compounds of formula (I)
- R 1 is halogen, lower-alkyl, lower-haloalkyl, lower-hydroxyalkyl, lower-alkoxy, lower- alkoxy-lower-alkyl, -C(0)-NR 9 R 10 , aryl, heteroaryl or NR 7 R 8 , wherein said aryl and said heteroaryl can be substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower-alkyl, lower-alkoxy, lower-alkoxy-lower-alkyl, lower-haloalkyl and lower-haloalkoxy;
- R is hydrogen, halogen, lower-alkyl, lower-haloalkyl, lower-hydroxyalkyl, lower-alkoxy or lower-alkoxy-lower-alkyl;
- R is hydrogen, lower-alkyl, lower-haloalkyl, lower-hydroxyalkyl, lower-alkoxy or lower- alkoxy-lo was- alkyl ;
- R 4 is hydroxyl, lower-alkoxy or NR 5 R 6 ;
- R 5 and R 6 are independently hydrogen, lower-alkyl, lower-haloalkyl, lower-hydroxyalkyl, lower-alkoxy-lower-alkyl, cycloalkyl or heterocyclyl, or R 5 and/or R 6 are lower-alkyl substituted by a substituent selected from the group consisting of heteroaryl, lower-alkyl- heteroaryl and lower-alkoxy-C(O)- , or
- R 5 and R 6 together with the nitrogen atom to which they are attached, form a heterocyclyl, bicyclo-heterocyclyl or spiro-heterocyclyl, wherein said heterocyclyl can be substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower-alkyl, lower-alkoxy, lower-alkoxy-lower-alkyl, lower-haloalkyl and oxo;
- R 7' and R 8° are independently hydrogen, lower-alkyl, lower-haloalkyl, lower-hydroxyalkyl, lower-alkoxy-lower-alkyl or cycloalkyl, or R 7 and R 8 , together with the nitrogen atom to which they are attached, form a heterocyclyl
- R 9 and R 10 are independently hydrogen, lower-alkyl, lower-haloalkyl, lower-hydroxyalkyl or lower-alkoxy-lower-alkyl, or a pharmaceutically acceptable salt thereof.
- the invention is concerned with a process for the manufacture of the above compounds, pharmaceutical preparations which contain such compounds as well as the use of these compounds for the production of pharmaceutical preparations.
- Schizophrenia is a progressive and devastating neurological disease characterized by episodic positive symptoms such as delusions, hallucinations, thought disorders and psychosis and persistent negative symptoms such as flattened affect, impaired attention and social withdrawal, and cognitive impairments (Lewis DA and Lieberman JA, Neuron, , 28:325-33, 2000).
- episodic positive symptoms such as delusions, hallucinations, thought disorders and psychosis
- persistent negative symptoms such as flattened affect, impaired attention and social withdrawal, and cognitive impairments
- For decades research has focused on the "dopaminergic hyperactivity" hypothesis which has led to therapeutic interventions involving blockade of the dopaminergic system (Vandenberg RJ and Aubrey KR., Exp. Opin. Ther. Targets, 5(4): 507-518, 2001; Nakazato A and Okuyama S, et al., Exp. Opin. Ther.
- Patents, 10(1): 75-98, 2000 This pharmacological approach, besides ameliorating positive symptoms in schizophrenic patients, poorly addresses negative and cognitive symptoms which are the best predictors of functional outcome (Sharma T., Br. J. Psychiatry, 174(suppl. 28): 44-51, 1999).
- current antipsychotic treatment is associated with adverse effects like weight gain, extrapyramidal symptoms or effects on glucose and lipid metabolism, related to their unspecific pharmacology.
- Cyclic nucleotides cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are ubiquitous second messengers responsible for mediating the biological response of a variety of extracellular signals, including neurotransmitters, light and hormones.
- cAMP and cGMP regulate a variety of intracellular processes particularly in neurons of the central nervous system by activating cAMP- and cGMP-dependent kinases which then phosphorylate proteins involved in the regulation of synaptic transmission, neuronal differentiation and survival.
- Phosphodiesterases are a family of widely expressed enzymes encoded by 21 different genes in humans, with each gene encoding several splice variants (Beavo, J., Physiol. Rev. 1995, 75, 725-748; Conti, M., Jin, S.L., Prog. Nucleic Acid Res. Mol. Biol. 1999, 63, 1-38; Soderling, S.H., Beavo, J.A., Curr. Opin. Cell Biol. 2000,12, 174-179, Manallack, D.T. et al. J. Med.Chem. 2005, 48 (10), 3449-3462).
- the PDE families differ in their substrate specificy for the cyclic nucleotides, their mechanism of regulation and their sensitivity to inhibitors. Moreover, they are differentially localized in the organism, among the cells of an organ and even within the cells. These differences lead to a differentiated involvement of the PDE families in the various physiological functions.
- PDE10A is a dual substrate PDE encoded by a single gene as reported in 1999 by three separate research groups (Fujishige K., et al., Eur J Biochem (1999) 266(3): 1118-1127, Soderling S.H., et al., ProcNatl Acad Sci USA (1999) 96(12):7071-7076, Loughney K., et al., Gene (1999) 234(1): 109- 117).
- PDE 1 OA is unique from other members of the multigene family with respect to amino acid sequence (779 aa), tissue-specific pattern of expression, affinity for cAMP and cGMP and the effect on PDE activity by specific and general inhibitors.
- PDE10A has one of the most restricted distribution of any PDE family being primarily expressed in the brain particularly in the nucleus accumbens and the caudate putamen. Additionally thalamus, olfactory bulb, hippocampus and frontal cortex show moderate levels of PDE10A expression. All these brain areas have been suggested to be involved in the pathophysiology of schizophrenia and psychosis, suggesting a central role of PDE10A in this devastating mental illness. Outside the central nervous system PDE10A transcript expression is also observed in peripheral tissues like thyroid gland, pituitary gland, insulin secreting pancreatic cells and testes (Fujishige, K. et al., J. Biol. Chem. 1999, 274, 18438-18445, Sweet, L.
- the striatal medium spiny neurons are the principal input site and first site for information integration in the basal ganglia circuit of the mammalian brain.
- the basal ganglia are a series of interconnected subcortical nuclei that integrate widespread cortical input with dopaminergic signaling to plan and execute relevant motor and cognitive patterns while suppressing unwanted or irrelevant patterns (Graybiel, A.M. Curr. Biol. 2000, 10, R509-R511 (2000).
- Papaverine, a relatively specific PDE 1 OA inhibitor, and PDE 1 OA-knockout mice have been used to explore the physiology of this enzyme and the possible therapeutic utility of PDE10A inhibition.
- Inhibition of this enzyme pharmacologically or through gene disruption causes a reduction in activity and a reduced response to psychomotor stimulants. Inhibition also reduces the conditioned avoidance response, a behavioural response that is predictive of clinical antipsychotic activity (Siuciak, J. A.; et al., Neuropharmacology 2006, 51 (2), 386-396; Siuciak, J.A.; et al., Neuropharmacology 2006, 51 (2), 374-385).
- PDE10A inhibition bears the potential to improve the negative and cognitive symptoms associated to schizophrenia.
- papaverine have been shown to attenuate the deficits in the extra-dimensional shift learning induced in rats by sub-chronic treatment with PCP, an animal paradigm of NMDA receptor hypofunction (Rodefer, J,S., et al., Eur. J. Neuroscience 2005, 2,: 1070- 1076).
- increased social interaction in PDE10A2-deficient mice have been observed (Sano, H. . Neurochem. 2008, 105, 546-556).
- Diseases that can be treated with PDE10A inhibitors include, but are not limited to, diseases thought to be mediated in part by dysfunction of the basal ganglia, of other parts of the central nervous system and of other PDE10A expressing tissues.
- diseases can be treated, where inhibition of PDE10A can have therapeutic effects.
- These diseases include, but are not limited to, certain psychotic disorders such as schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder or substance-induced psychotic disorder, anxiety disorders such as panic disorder, obsessive-compulsive disorder, acute stress disorder or generalized anxiety disorder, obsessive/compulsive disorders, drug addictions, movement disorders such as Parkinson's disease or restless leg syndrome, cognition deficiency disorders such as Alzheimer's disease or multi-infarct dementia, mood disorders such as depression or bipolar disorders, or neuropsychiatric conditions such as psychosis, attention-deficit/hyperactivity disorder (ADHD) or related attentional disorders.
- psychotic disorders such as schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder or substance-induced psychotic disorder, anxiety disorders such as panic disorder, obsessive-compulsive disorder, acute stress disorder or generalized anxiety disorder, obsessive/compulsive disorders, drug addictions, movement disorders such as Parkinson's disease or restless leg
- the compounds of the present invention are also suitable for the treatment of diabetes and related disorders such as obesity by regulating the cAMP signaling system.
- PDE10A inhibitors might also be useful in preventing neurons from undergoing apoptosis by raising cAMP and cGMP levels and, thus, might possess anti-inflammatory properties.
- Neurodegenerative disorders treatable with PDE10A inhibitors include, but are not limited to, as Alzheimer's disease, Huntington's disease, Parkinson's disease, multiple sclerosis, stroke or spinal cord injury.
- cAMP and cGMP The growth of cancer cells is inhibited by cAMP and cGMP.
- PDEIOA inhibitors can also be used for the treatment of different solid tumors and hematological malignancies such as renal cell carcinoma or breast cancer.
- one or more means from one substituent to the highest possible number of substitution, i.e. replacement of one hydrogen up to replacement of all hydrogens by substituents.
- lower is used to mean a group consisting of one to seven, more specifically of one to four carbon atom(s).
- halogen refers to fluorine, chlorine, bromine and iodine, more speficially fluorine, chlorine and bromine.
- alkyl refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, more specifically one to sixteen carbon atoms, yet more specifically one to ten carbon atoms.
- lower-alkyl refers to a branched or straight-chain monovalent alkyl radical of one to seven carbon atoms, more specifically one to four carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like.
- lower-haloalkyl alone or in combination with other groups, refers to lower- alkyl groups which are mono- or multiply substituted with halogen, particularly fluoro.
- lower-haloalkyl groups are e.g. -CFH 2 , -CF 2 H, -CF 3 , CF 3 CH 2 -, CF 3 (CH 2 ) 2 -, (CF 3 ) 2 CH- and CF 2 H-CH 2 -.
- lower-hydroxyalkyl refers to lower-alkyl groups which are substituted by 1 to 3 hydroxyl groups.
- Examples of lower-hydroxyalkyl groups are e.g. hydroxy-methyl, 2-hydroxy- ethyl, hydroxy propyl, 3 -hydroxy-propyl, 2-hydroxy-propyl, 3-hydroxy-prop-2-yl, 2,3- dihydroxy-propyl and l,3-dihydroxy-prop-2-yl.
- -C(0)-NH-lower-haloalkyl refers to groups in which one hydrogen of -C(O)- NH 2 is substituted by lower-haloalkyl.
- alkoxy refers to the group R'-O-, wherein R' is an alkyl.
- lower- alkoxy alone or in combination with other groups, refers to the group R'-O-, wherein R' is a lower-alkyl.
- lower-alkoxy-lower-alkyl refers to lower-alkyl groups which are mono- or multiply substituted with lower-alkoxy.
- Examples of lower-alkoxy-lower-alkyl groups are e.g. CH 2 -0-CH 3 , -CH 2 -CH 2 -0-CH 3 and -CH 2 -0-CH 2 -CH 3 .
- lower-haloalkoxy refers to a group of the formula lower-haloalkyl-O-.
- amino refers to a monovalent group that has a nitrogen atom with two hydrogen atoms (represented by -NH 2 ).
- oxo when referring to substituents on heterocyclyl means that an oxygen atom is attached to the heterocyclyl ring. Thereby, the “oxo” may either replace two hydrogen atoms on a carbon atom, or it may simply be attached to sulfur, so that the sulfur exists in oxidized form, i.e. bearing one or two oxygens.
- cycloalkyl refers to a monovalent carbocyclic radical of 3 to 10 carbon atoms, more specifically 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
- heterocyclyl refers to a monovalent saturated 4- to 6-membered monocyclic ring containing one, two or three ring heteroatoms independently selected from N, O and S, the remaining ring atoms being carbon atoms, wherein the point of attachment can be through either a carbon atom or a heteroatom.
- heterocyclyl are e.g. morpholinyl and piperidinyl.
- bicyclo-heterocyclyl refers to a monovalent saturated 7- to 10-membered bicyclic ring containing one, two or three ring heteroatoms independently selected from N, O and S, the remaining ring atoms being carbon atoms, wherein the point of attachment can be through either a carbon atom or a heteroatom.
- heterocyclyl are e.g. 2-oxa-5- azabicyclo[2.2.1]heptane and l,4-diaza-bicyclo[3.2.1]octane.
- spiro-heterocyclyl refers to a monovalent saturated 7- to 11-membered bicyclic moiety with the rings connected through one atom, containing one, two or three ring heteroatoms independently selected from N, O and S, the remaining ring atoms being carbon atoms, wherein the point of attachment can be through either a carbon atom or a heteroatom.
- An example of a spiro-heterocyclyl ring is 2-oxa-6-azaspiro[3.3]heptane.
- aryl refers to a monovalent aromatic hydrocarbon ring.
- the aryl group more specifically includes 6 to 10 carbon atoms. Examples of aryl groups are e.g. phenyl.
- heteroaryl refers to an aromatic 5- or 6-membered monocyclic ring or 9- or
- 10-membered bicyclic ring which comprises 1, 2 or 3 atoms independently selected from nitrogen, oxygen and/or sulphur, such as pyridinyl.
- lower-alkyl-heteroaryl refers to heteroaryl which is substituted with lower- alkyl.
- Examples of lower-alkyl-heteroaryl are e.g. methylpyridinyl.
- Compounds of formula (I) can form pharmaceutically acceptable salts.
- pharmaceutically acceptable salts are salts of compounds of formula (I) with physiologically compatible mineral acids, such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
- physiologically compatible mineral acids such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid
- organic acids such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
- pharmaceutically acceptable salts refers
- a COOH group can further form salts with bases.
- salts examples include alkaline, earth- alkaline and ammonium salts such as e.g. Na-, K-, Ca- and trimethylammonium salt.
- pharmaceutically acceptable salts also refers to such salts. Particular salts are those obtained by the addition of an acid.
- esters embraces derivatives of the compounds of formula (I), in which a carboxy group has been converted to an ester.
- esters are methyl, ethyl, propyl, butyl and benzyl esters.
- pharmaceutically acceptable esters furthermore embraces compounds of formula (I) in which hydroxy groups have been converted to the corresponding esters with inorganic or organic acids such as, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms.
- R 4 is hydroxyl, lower-alkoxy or NR 5 R 6 ;
- R 5 and R 6 are independently hydrogen, lower-alkyl, lower-haloalkyl, lower-hydroxyalkyl, lower-alkoxy-lower-alkyl, cycloalkyl or heterocyclyl, or R 5 and/or R 6 are lower-alkyl substituted by a substituent selected from the group consisting of heteroaryl, lower-alkyl- heteroaryl and lower-alkoxy-C(O)-, or
- R 5 and R 6 together with the nitrogen atom to which they are attached, form a heterocyclyl, bicyclo-heterocyclyl or spiro-heterocyclyl, wherein said heterocyclyl can be substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower-alkyl, lower-alkoxy, lower-alkoxy-lower-alkyl, lower-haloalkyl and oxo;
- R 7' and R 8° are independently hydrogen, lower-alkyl, lower-haloalkyl, lower-hydroxyalkyl, lower-alkoxy-lower-alkyl or cycloalkyl, or
- R 7 and R 8 together with the nitrogen atom to which they are attached, form a heterocyclyl
- R 9 and R 10 are independently hydrogen, lower-alkyl, lower-haloalkyl, lower-hydroxyalkyl or lower-alkoxy-lower-alkyl, or a pharmaceutically acceptable salt thereof.
- the present invention also relates to compounds of formula (I)
- R is hydrogen or lower-alkyl;
- R 4 is hydroxyl, lower-alkoxy or NR 5 R 6 ;
- R 5 and R 6 are independently hydrogen, lower-alkyl, lower-haloalkyl, lower-alkoxy-lower- alkyl, lower-alkyl substituted by lower-alkyl-heteroaryl or heterocyclyl, or
- R 5 and R 6 together with the nitrogen atom to which they are attached, form a heterocyclyl which can be substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower-alkyl, lower-alkoxy, lower-haloalkyl and oxo;
- R 7' and R 8° are independently lower-alkyl or, together with the nitrogen atom to which they are attached, form a morpholinyl ring. or pharmaceutically acceptable salts thereof.
- the compounds of formula (I) can have one or more asymmetric C atoms and can therefore exist as an enantiomeric mixture, mixture of stereoisomers or as optically pure compounds.
- the compounds of formula (I) include all diastereomers, tautomers, racemates and mixtures thereof.
- a particular embodiment of the present invention relates to compounds of formula (I) as described above, wherein R 1 is halogen, lower-alkyl, -C(0)-NR 9 R 10 , phenyl, pyridinyl or NR 7 R 8 , wherein said phenyl and said pyridinyl can be substituted by 1 to 3 substituents independently selected from the group consisting of hydroxyl, halogen, lower-alkyl, lower-alkoxy, lower- haloalkyl and lower-haloalkoxy; R 7 and R 8 are independently lower-alkyl, lower-haloalkyl or cycloalkyl, or R 7 and R 8 are, together with the nitrogen atom to which they are attached, form pyrrolidin-l-yl, 2-oxopyrrolidin-l-yl or morpholin-4-yl; and R 9 and R 10 are independently hydrogen, lower-alkyl, lower-haloalkyl or lower-alkoxy-lower-alkyl
- R 1 is phenyl, 3 -fluorophenyl, 2-methoxyphenyl, 3-methoxy-phenyl, pyridin-3-yl, 2-fluoropyridin-4-yl, dimethylamino, ethyl-methyl-amino cyclopropyl-methyl-amino, pyrrolidin-l-yl or morpholin-4- yi-
- R 1 is phenyl, 3 -fluorophenyl, 2-methoxyphenyl, 3-methoxy-phenyl, pyridin-3-yl, 2-fluoropyridin-4-yl, dimethylamino, ethyl-methyl-amino cyclopropyl-methyl-amino, pyrrolidin-l-yl or morpholin-4- yi-
- Another particular embodiment of the present invention relates to compounds of formula
- R is hydrogen, halogen or lower-alkyl, more specifically hydrogen.
- Yet another particular embodiment of the present invention relates to compounds of formula (I) as described above, wherein R is lower-alkyl, more specifically methyl.
- a particular embodiment of the present invention relates to compounds of formula (I) as described above, wherein R 4 is hydroxyl, lower- alkoxy or NR 5 R 6 ;
- R 5 and R 6 are independently hydrogen, lower-alkyl, lower-haloalkyl, lower-hydroxyalkyl, lower-alkoxy-lower-alkyl, cyclopropyl, cyclopentyl, oxetanyl or tetrahydrofuranyl, or R 5 and/or R 6 are lower-alkyl substituted by a substituent selected from the group consisting of lower-alkyl -pyridinyl and methoxycarbonyl, or
- heterocyclyl selected from the group consisting of azetidinyl, pyrrolidinyl, piperazinyl, morpholinyl and thiomorpholinyl, wherein said heterocyclyl can be substituted by 1 to 3 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy and oxo, or R 5 and R 6 , together with the nitrogen atom to which they are attached, form 2-oxa-5-azabicyclo[2.2.1]heptanyl, 2-oxa-6-azaspiro[3.3]heptanyl or 1,4-diaza- bicyclo[3.2.1]octanyl.
- Another particular embodiment of the present invention relates to compounds of formula
- R 4 is NR 5 R 6 ;
- R 5 and R 6 are independently methyl, ethyl, 2-fluoroethyl, 2-methoxyethyl or cyclopropyl, or
- azetidinyl selected from the group consisting of azetidinyl, 3-fluoroazetidinyl, morpholin-4-yl and pyrrolidinyl, or R 5 and R 6 , together with the nitrogen atom to which they are attached, form 2-oxa-6-azaspiro[3.3]heptanyl or l,4-diaza-bicyclo[3.2.1]octanyl.
- Particular compounds of formula (I) are those selected from the group consisting of: methyl l-methyl-5-(2-phenyl-[l,2,4]triazolo[l,5-a]pyridin-7-ylcarbamoyl)-lH-pyrazole-4- carboxylate,
- the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
- the invention further relates to a process for the manufacture of compounds of formula (I) as defined above, which process comprises: reacting a compound of formula (2)
- R 1 , R2 , R 3 and R 4 are as defined above and, if desired, converting the compounds into pharmaceutically acceptable salts thereof.
- the reaction described above can be carried out under conditions as described in the description and examples or under conditions well known to the person skilled in the art.
- the compounds of formula (2) and (3) can be prepared by methods known in the art or as described below or in analogy thereto.
- the present invention also relates to compounds of formula (I) as defined above, when prepared by a process as described above.
- Compounds of formula 1 can be prepared from building blocks 2 and 3 according to Scheme 1.
- the conversion commonly known as amide coupling, can be achieved in several ways.
- the acid 2 is activated with a coupling reagent, such as 2-(lH- benzotriazole-l-yl)-l,l,3,3-tetramethyluronium tetrafluoroborate (TBTU), or propylphosphonic anhydride, and converted by addition of amine 3 to the desired product, 1.
- the acid 2 is activated by transformation into an acid chloride, e.g. by reaction with thionyl chloride.
- the acid chloride is then converted by addition of the amine 3 to the desired product, 1.
- a base e.g. diisopropylethylamine (DIPEA), is usually added to bind liberated HC1.
- DIPEA diisopropyle
- 2-aminopyridine (4) is reacted with O-mesitylenesulfonyl hydroxyl amine 5 to form salt 6.
- Salt 6 is then reacted with a compound 7 such as a (substituted) benzoic acid chloride, with a suitable base, such as pyridine, to give compound 8.
- Compound 8 is then converted to amine 3 by methods well known in the art. For example, if Y is bromine, 8 can be used in a palladium- catalyzed cross coupling reaction using a suitable nitrogen compound, such as carbamic acid tert-butyl ester, and a suitable ligand, such as Xantphos, to yield, after deprotection, amine 3.
- compound 8 can be saponified with a suitable base such as lithium hydroxide and then be converted with diphenylphosphoryl azide to yield, after deprotection, the desired amine 3.
- 2-Amino-4-bromopyridine as example of 2-aminopyridines 4, carbamic acid tert-butyl ester, Xantphos and diphenylphosphoryl azide are commercially available; compounds 4, 5 and 7 are either commercially available, or can be prepared by methods well known in the art.
- compounds of formula 1 with -C(0)-R 4 being a lower alkoxycarbonyl group can be further transformed according to Scheme 4.
- compounds of the general formula 1-COOEt can be saponified by suitable methods, e.g. by reaction with LiOH, to give 1-COOH.
- a suitable reagent such as TBTU
- 1-COOH can be converted with a primary or secondary amine to l-CONR 2 .
- 1-COOEt can be directly converted into l-CONR 2 , e.g. by reaction with an amine such as methylamine.
- compounds of formula 3 can be prepared according to Scheme 5: A suitably substituted 4-pyridinecarboxylic acid alkyl ester of formula 12 is reacted with O- mesitylenesulfonyl hydroxyl amine 5 to form salt 13. Salt 13 is then reacted with a compound of formula 14 such as a (substituted) benzonitrile, with a suitable base such as potassium hydroxide and an oxidizing agent such as copper(II) acetate in a suitable solvent such as ethanol or water to form the compounds of formula 15a and 15b, which by methods well known in the art can be converted to the amines 3a and 3b.
- a compound of formula 14 such as a (substituted) benzonitrile
- 3-Methyl-4-pyridinecarboxylic acid ethyl ester and O-mesitylenesulfonyl hydroxyl amine are known.
- Other compounds of formula 12 can be prepared by methods well known in the art.
- Compounds 14 are either commercially available, or can be prepared by methods well known in the art.
- compounds of formula 3, with R 1 being NR 7 R 8 can be prepared according to Scheme 6:
- a suitably substituted 2-aminopyridine (4) is reacted with ethoxycarbonyl- isothiocyanate (17) to form thiourea 18, which can be cyclized using hydroxylamine and a suitable base such as diisopropylethylamine to a compound of formula 19.
- thiourea 18 can be cyclized using hydroxylamine and a suitable base such as diisopropylethylamine to a compound of formula 19.
- This can be converted by methods well known in the art to compound 22 and further to the desired amine of formula 3c.
- compounds of formula 19 can be treated with a nitrite such as sodium nitrite or alkyl nitrite such as tert-butyl nitrite and a bromide such as copper(II) bromide or benzyl - triethylammonium bromide in a suitable solvent such as acetonitrile or bromoform to form bromide 20.
- a nitrite such as sodium nitrite or alkyl nitrite such as tert-butyl nitrite and a bromide such as copper(II) bromide or benzyl - triethylammonium bromide in a suitable solvent such as acetonitrile or bromoform
- Bromide 20 can then be reacted with an amine of formula 21 in a suitable solvent such as THF or ethanol.
- a base e.g. diisopropylethylamine (DIPEA), may be added to the reaction.
- amines 21 are either commercially available, or can be prepared by methods well known in the art.
- the corresponding salts with acids can be obtained by standard methods known to the person skilled in the art, e.g. by dissolving the compound of formula (I) in a suitable solvent such as e.g. dioxane or THF and adding an appropriate amount of the corresponding acid.
- a suitable solvent such as e.g. dioxane or THF
- the products can usually be isolated by filtration or by chromatography.
- the conversion of a compound of formula (I) into a pharmaceutically acceptable salt with a base can be carried out by treatment of such a compound with such a base.
- One possible method to form such a salt is e.g. by addition of 1/n equivalents of a basic salt such as e.g.
- M(OH) n wherein M is metal or ammonium cation and n is number of hydroxide anions, to a solution of the compound in a suitable solvent (e.g. ethanol, ethanol-water mixture, tetrahydrofuran-water mixture) and to remove the solvent by evaporation or lyophilisation.
- a suitable solvent e.g. ethanol, ethanol-water mixture, tetrahydrofuran-water mixture
- the conversion of compounds of formula (I) into pharmaceutically acceptable esters can be carried out e.g. by treatment of a suitable carboxy group present in the molecule with a suitable alcohol using e.g. a condensating reagent such as benzotriazol-1- yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), N,N- dicylohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N' -ethylcarbodiimide
- a condensating reagent such as benzotriazol-1- yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), N,N- dicylohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N' -ethylcarbodiimide
- the compounds of formula (I) as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth above. Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in analogy thereto. As described above, the novel compounds of the present invention have been found to inhibit PDEIOA activity. The compounds of the present invention can therefore be used, either alone or in combination with other drugs, for the treatment and/or prophylaxis of diseases which are modulated by PDEIOA inhibitors.
- These diseases include, but are not limited to, certain psychotic disorders such as schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder or substance-induced psychotic disorder, anxiety disorders such as panic disorder, obsessive/compulsive disorders, acute stress disorder or generalized anxiety disorder, drug addictions, movement disorders such as Parkinson's disease or restless leg syndrome, cognition deficiency disorders such as Alzheimer's disease or multi- infarct dementia, mood disorders such as depression or bipolar disorders, or neuropsychiatric conditions such as psychosis, attention-deficit/hyperactivity disorder (ADHD) or related attentional disorders.
- psychotic disorders such as schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder or substance-induced psychotic disorder, anxiety disorders such as panic disorder, obsessive/compulsive disorders, acute stress disorder or generalized anxiety disorder, drug addictions, movement disorders such as Parkinson's disease or restless leg syndrome, cognition deficiency disorders such as Alzheimer's disease or multi- infarct dementia,
- diabetes and related disorders such as type 2 diabetes mellitus, neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, Parkinson's disease, multiple sclerosis, stroke or spinal cord injury, solid tumors and hematological malignancies such as renal cell carcinoma or breast cancer.
- the invention therefore also relates to compounds as described above for use as therapeutically active substance.
- the invention also relates to pharmaceutical compositions comprising a compound as descriebd above and a therapeutically inert carrier.
- the inventino relates to the use of a compound as described above for the treatment or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance- induced psychotic disorder, anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention-deficit/hyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, hematological malignancies, renal cell carcinoma or breast cancer.
- the invention relates to the use of a compound as described above for the preparation of a medicament for the treatment or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance-induced psychotic disorder, anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention- deficit/hyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, hematological malignancies, renal cell carcinoma or breast cancer.
- the invention also relates to a compound as described above for the treatment or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance-induced psychotic disorder, anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention- deficit/hyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, hematological malignancies, renal cell carcinoma or breast cancer.
- the invention further relates to a compound as described above, when manufactured according to a process as described above.
- the invention relates to a method for the treatment or prophylaxis of psychotic disorders, schizophrenia, positive, negative and/or cognitive symptoms associated with schizophrenia, delusional disorder, substance-induced psychotic disorder, anxiety disorders, panic disorder, obsessive/compulsive disorders, acute stress disorder, generalized anxiety disorder, drug addictions, movement disorders, Parkinson's disease, restless leg syndrome, cognition deficiency disorders, Alzheimer's disease, multi-infarct dementia, mood disorders, depression, bipolar disorders, neuropsychiatric conditions, psychosis, attention- deficit/hyperactivity disorder, attentional disorders, diabetes and related disorders, type 2 diabetes mellitus, neurodegenerative disorders, Huntington's disease, multiple sclerosis, stroke, spinal cord injury, solid tumors, hematological malignancies, renal cell carcinoma or breast cancer, which method comprises administering an effective amount of a compound as described above.
- Prevention and/or treatment of schizophrenia is a particular indication. Yet particular indication is prevention and/or treatment of positive, negative and/or cognitive symptoms associated with schizophrenia.
- PDE10 activity of the compounds of the present invention was determined using a Scintillation Proximity Assay (SPA)-based method similar to the one previously described (Fawcett, L. et al., ProcNatl Acad Sci USA (2000) 97(7):3702-3707).
- SPA Scintillation Proximity Assay
- the human PDE10A full length assay was performed in 96-well micro titer plates.
- a range of concentrations of the potential inhibitor was used to generate data for calculating the concentration of inhibitor resulting in 50% of the effect (e.g. IC 5 0, the concentration of the competitor inhibiting PDE10A activity by 50%).
- Non-specific activity was tested without the enzyme.
- the reaction was initiated by the addition of the substrate solution (cGMP and [ H]- cGMP) and allowed to progress for 20 minutes at room temperature.
- the reaction was terminated by adding 25 ⁇ of YSi-SPA scintillation beads (GE Healthcare, cat. # RPNQ0150) in 18 mM zinc sulphate solution (stop reagent). After 1 h under shaking, the plate was centrifuged one minute at 170 g to allow beads to settle. Afterwards, radioactive counts were measured on a Perkin Elmer TopCount Scintillation plate reader.
- the compounds according to formula (I) have an IC 5 0 value below 10 ⁇ , more specifically below 5 ⁇ , yet more specifically below 1 ⁇ .
- the following table shows data for some examples.
- the compounds of formula (I) and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or suspensions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils.
- perorally e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or suspensions or infusion solutions, or topically,
- Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials.
- lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatin capsules.
- Suitable carrier materials for soft gelatin capsules are, for example, vegetable oils, waxes, fats and semi- solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatin capsules).
- Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like.
- Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils.
- Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
- Suitable carrier materials for topical preparations are glycerides, semi- synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
- Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
- the dosage of the compounds of formula (I) can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 0.1 to 2000 mg, especially about 1 to 500 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.
- the pharmaceutical preparations conveniently contain about 0.1-500 mg, more specifically 1-200 mg, of a compound of formula (I).
- the solvent is removed in vacuo and the brown residue partitioned between ethyl acetate and water.
- the aqueous layer is extracted twice with ethyl acetate and the combined organic layers are washed with water (3 x 120 ml) and with brine and dried with magnesium sulfate.
- the solution is concentrated in vacuo to ca 80 ml: crystallization.
- the crude material is loaded on silica and purified by flash chromatography on a 20 g silica column using heptane / ethyl acetate 10-100 % as eluent affording 6-methyl-2- phenyl-[l,2,4]triazolo[l,5-a]pyridin-7-ylamine (43 mg, 28%) as an off-white solid, mp.: > 250°C.
- MS: m/z 225.3 (M+H + ).
- the hydrochloride can be prepared by stirring in tetrahydrofurane/6N hydrochloric acid in diethylether (1:6) for 2 hours and final evaporation to dryness. Light brown solid (quant.).
- N-(2-fluoroethyl)-N,l -dimethyl- lH-pyrazole-4-carboxamide 500 mg, 2.7 mmol
- THF 10.0 ml
- 1,1,4,7,7- Pentamethyldiethylenetriamine 621 ⁇ , 2.97 mmol
- tBuLi 1.6 M in pentane, 2.53 ml, 4.05 mmol
- reaction mixture is poured on sat. aqueous sodium bicarbonate solution (60 ml) and extracted with ethyl acetate (2 x 50 ml).
- ethyl acetate 2 x 50 ml.
- the combined organic layer is washed once with water, once with brine, dried with magnesium sulfate and the solvent is removed in vacuo.
- Example 35 4-(Azetidine- 1 -carbonyl)-N-(2-(dimethylamino)- [ 1 ,2,4] triazolo[ 1 ,5-a]pyridin-7-yl)- 1 -methyl- lH-pyrazole-5-carboxamide a) l-ethoxycarbonyl-3-(4-bromo-pyridin-2-yl)-thiourea
- benzyltriethylammonium bromide (12.2 g, 44.6 mmol) and sodium nitrite (10.3 g, 149 mmol) in bromoform (78.1 ml, 893 mmol) is stirred for 30 minutes at 25 °C, then dichloroacetic acid (2.46 ml, 29.8 mmol) is added and the resulting solution (wrapped in aluminium foil to protect the mixture from light) is stirred for 18 hours at room temperature. After addition of 200 ml of water and stirring for 30 minutes, the mixture is extracted 3 times with dichloromethane, the organic layers are combined, washed with water, dried with magnesium sulfate and the solvents are evaporated under reduced pressure.
- Example 43 4-(3-Fluoroazetidine- 1 -carbonyl)- 1 -methyl-N-(2-morpholino-[ 1 ,2,4] triazolo[ 1 ,5-a]pyridin-7-yl)- lH-pyrazole-5-carboxamide
- Example 44 4-(Azetidine- 1 -carbonyl)- 1 -methyl-N-(2-(pyridin-3-yl)- [ 1 ,2,4] triazolo[ 1 ,5-a]pyridin-7-yl)- 1H- pyrazole- 5 -c arboxamide
- Nitrogen is bubbled for 10 minutes through a mixture of tert-butyl 2-bromo-[l,2,4]triazolo[l,5- a]pyridin-7-ylcarbamate (1.39 g, 4.44 mmol) and pyridin-3-ylboronic acid (818 mg, 6.66 mmol) in dioxane (23.8 ml) and sat. aqueous sodium carbonate sol. (5.94 ml), then 1,1'- bis(diphenylphosphino)ferrocene palladium (II) chloride (181 mg, 222 ⁇ ) is added and the resulting mixture is fluxed for 18 hours under nitrogen atmosphere.
- propylphosphonic anhydride (50% in ethyl acetate, 329 ⁇ , 558 ⁇ ) and ⁇ , ⁇ - diisopropylethylamine (114 ⁇ , 669 ⁇ ) in tetrahydrofurane (7 ml) is refluxed for 18 hours.
- the mixture is dissolved in ethyl acetate and washed with sodium bicarbonate solution and brine.
- the organic layer is separated, dried with magnesium sulfate and the solvent is removed under reduced pressure.
- pyrazole-4-carboxylic acid 100 mg, 223 ⁇
- pyrrolidine 148 ⁇ , 1.79 mmol
- propylphosphonic anhydride 50% in ethyl acetate, 329 ⁇ , 558 ⁇
- ⁇ , ⁇ - diisopropylethylamine 114 ⁇ , 669 ⁇
- tetrahydrofurane 7 ml
- Example 51 4-(3-Fluoro-azetidine- l-carbonyl)-2-methyl-2H-pyrazole-3-carboxylic acid (2-isopropyl- [ 1 ,2,4] triazolo[ 1 ,5-a]pyridin-7-yl)-amide
- the resulting mixture was heated to 100 °C and stirred for 2.5 days (weekend) under argon atmosphere.
- the crude material was applied on silicagel and purified by flash chromatography over a 50 g silicagel column using heptane / ethyl acetate 10-50 % as eluent affording [2-(ethyl- methyl-amino)-[l,2,4]triazolo[l,5-a]pyridin-7-yl]-carbamic acid tert-butyl ester (509 mg, 81.2%) as a white solid.
- the product was prepared in the same manner as described in example 62 using 7-(4-(azetidine- l-carbonyl)-l-methyl-lH-pyrazole-5-carboxamido)-[l,2,4]triazolo[l,5-a]pyridine-2-carboxylic acid (130 mg, 264 ⁇ ) and ethanamine hydrochloride (215 mg, 2.64 mmol) as starting materials.
- the product was prepared in the same manner as described in example 62 using 7-(4-(azetidine- l-carbonyl)-l-methyl-lH-pyrazole-5-carboxamido)-[l,2,4]triazolo[l,5-a]pyridine-2-carboxylic acid (140 mg, 0.379 mmole) and 2-methoxyethanamine (163 ⁇ , 1.9 mmole) as starting materials.
- the product was prepared in the same manner as discribed in example 66 using 4-(azetidine-l- carbonyl)-N-(2-bromo-[l,2,4]triazolo[l,5-a]pyridin-7-yl)-l-methyl-lH-pyrazole-5-carboxamide (150 mg, 371 ⁇ ) and 2-methylpyridin-4-ylboronic acid (76.2 mg, 557 ⁇ ) as starting materials.
- the product was prepared in the same manner as discribed in example 66 using 4-(azetidine-l- carbonyl)-N-(2-bromo-[l,2,4]triazolo[l,5-a]pyridin-7-yl)-l-methyl-lH-pyrazole-5-carboxamide (150 mg, 371 ⁇ ) and 5-methylpyridin-3-ylboronic acid (76.2 mg, 557 ⁇ ) as starting materials.
- the product was prepared in the same manner as discribed in example 66 using N-(2-bromo- [l,2,4]triazolo[l,5-a]pyridin-7-yl)-l-methyl-4-(morpholine-4-carbonyl)-lH-pyrazole-5- carboxamide (200 mg, 461 ⁇ ) and 2-methoxyphenylboronic acid (140 mg, 921 ⁇ ) as starting materials.
- the crude material was applied on silicagel and purified by flash
- Example 70 4-(Azetidine-l-carbonyl)-2-methyl-2H-pyrazole-3-carboxylic acid ⁇ 2-[(2-fluoro-ethyl)-methyl- amino] - [ 1 ,2,4] triazolo [ 1 ,5-a]pyridin-7-yl ⁇ -amide a) (7-Bromo- [ 1 ,2,4] triazolo[ 1 ,5-a]pyridin-2-yl)-(2-fluoro-ethyl)-methyl-amine
- the product was prepared in the same manner as discribed in example 65a) using 7-bromo- [l,2,4]triazolo[l,5-a]pyridin-2-yl)-(2-fluoro-ethyl)-methyl-amine (0.710 g, 2.6 mmol) as starting material.
- the product was prepared in the same manner as described in example 65c) using N2-(2-fluoro- ethyl)-N2-methyl-[l,2,4]triazolo[l,5-a]pyridine-2,7-diamine hydrochloride (1.3 g, 5.3 mmol) and 2-methyl-2H-pyrazole-3,4-dicarboxylic acid-4-ethyl ester (1.08 g, 5.45 mmol) as starting materials. The solvent was evaporated and the resulting yellowish oil was triturated with sat. sodium hydrogencarbonate solution.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK11791543.9T DK2649070T3 (en) | 2010-12-07 | 2011-12-05 | TRIAZOLPYRIDINE COMPOUNDS |
EP11791543.9A EP2649070B1 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
CA2816829A CA2816829C (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
EA201390799A EA022607B1 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
KR1020137016458A KR20130128426A (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
JP2013542480A JP5932828B2 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
UAA201308329A UA109037C2 (en) | 2010-12-07 | 2011-12-05 | Triazolepyridins |
BR112013013912A BR112013013912A2 (en) | 2010-12-07 | 2011-12-05 | triazolopyridine compounds |
CN201180057674.XA CN103237803B (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
ES11791543.9T ES2520647T3 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine Compounds |
AU2011340685A AU2011340685A1 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
MX2013006054A MX2013006054A (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds. |
SG2013037676A SG190305A1 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
SI201130309T SI2649070T1 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
RS20140574A RS53677B1 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
PL11791543T PL2649070T3 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
IL225969A IL225969A0 (en) | 2010-12-07 | 2013-04-25 | Triazolopyridine compounds |
ZA2013/03811A ZA201303811B (en) | 2010-12-07 | 2013-05-24 | Triazolopyridine compounds |
MA36027A MA35086B1 (en) | 2010-12-07 | 2013-06-20 | Compound of triazolopyridine |
HRP20141200AT HRP20141200T1 (en) | 2010-12-07 | 2014-12-11 | Triazolopyridine compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10194014 | 2010-12-07 | ||
EP10194014.6 | 2010-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012076430A1 true WO2012076430A1 (en) | 2012-06-14 |
Family
ID=45099086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/071685 WO2012076430A1 (en) | 2010-12-07 | 2011-12-05 | Triazolopyridine compounds |
Country Status (30)
Country | Link |
---|---|
US (1) | US8349824B2 (en) |
EP (1) | EP2649070B1 (en) |
JP (1) | JP5932828B2 (en) |
KR (1) | KR20130128426A (en) |
CN (1) | CN103237803B (en) |
AR (1) | AR084152A1 (en) |
AU (1) | AU2011340685A1 (en) |
BR (1) | BR112013013912A2 (en) |
CA (1) | CA2816829C (en) |
CL (1) | CL2013001591A1 (en) |
CO (1) | CO6741154A2 (en) |
CR (1) | CR20130239A (en) |
CY (1) | CY1115863T1 (en) |
DK (1) | DK2649070T3 (en) |
EA (1) | EA022607B1 (en) |
EC (1) | ECSP13012667A (en) |
ES (1) | ES2520647T3 (en) |
HR (1) | HRP20141200T1 (en) |
IL (1) | IL225969A0 (en) |
MA (1) | MA35086B1 (en) |
MX (1) | MX2013006054A (en) |
PE (1) | PE20140226A1 (en) |
PL (1) | PL2649070T3 (en) |
PT (1) | PT2649070E (en) |
RS (1) | RS53677B1 (en) |
SG (1) | SG190305A1 (en) |
SI (1) | SI2649070T1 (en) |
UA (1) | UA109037C2 (en) |
WO (1) | WO2012076430A1 (en) |
ZA (1) | ZA201303811B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013117610A1 (en) * | 2012-02-09 | 2013-08-15 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives |
EP2757883A1 (en) * | 2011-09-22 | 2014-07-30 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
WO2014118039A1 (en) | 2013-01-31 | 2014-08-07 | F. Hoffmann-La Roche Ag | Radiolabeled compounds |
WO2014133046A1 (en) | 2013-02-27 | 2014-09-04 | 持田製薬株式会社 | Novel pyrazole derivative |
WO2014177493A1 (en) | 2013-04-30 | 2014-11-06 | F. Hoffmann-La Roche Ag | Pd-CATALYZED COUPLING OF PYRAZOLE AMIDES |
US9518055B2 (en) | 2011-09-22 | 2016-12-13 | Merck Sharp & Dohme | Imidazopyridyl compounds as aldosterone synthase inhibitors |
KR20170032328A (en) | 2014-07-30 | 2017-03-22 | 모찌다 세이야쿠 가부시끼가이샤 | Pyrazole derivative manufacturing method |
KR20170032329A (en) | 2014-07-30 | 2017-03-22 | 모찌다 세이야쿠 가부시끼가이샤 | Pyrazole derivative manufacturing method |
RU2681941C2 (en) * | 2013-05-31 | 2019-03-14 | Ниссан Кемикал Индастриз, Лтд. | Heterocyclic amide compound |
WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
US11883385B2 (en) | 2020-06-05 | 2024-01-30 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
AU2022214289A1 (en) * | 2021-01-28 | 2023-08-10 | Noema Pharma Ag | Methods for the treatment of childhood-onset fluency disorder |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
WO2009152825A1 (en) * | 2008-06-20 | 2009-12-23 | H. Lundbeck A/S | Novel phenylimidazole derivatives as pde10a enzyme inhibitors |
-
2011
- 2011-12-01 US US13/308,588 patent/US8349824B2/en active Active
- 2011-12-05 CN CN201180057674.XA patent/CN103237803B/en active Active
- 2011-12-05 WO PCT/EP2011/071685 patent/WO2012076430A1/en active Application Filing
- 2011-12-05 KR KR1020137016458A patent/KR20130128426A/en not_active Application Discontinuation
- 2011-12-05 JP JP2013542480A patent/JP5932828B2/en active Active
- 2011-12-05 RS RS20140574A patent/RS53677B1/en unknown
- 2011-12-05 ES ES11791543.9T patent/ES2520647T3/en active Active
- 2011-12-05 SG SG2013037676A patent/SG190305A1/en unknown
- 2011-12-05 DK DK11791543.9T patent/DK2649070T3/en active
- 2011-12-05 BR BR112013013912A patent/BR112013013912A2/en not_active Application Discontinuation
- 2011-12-05 SI SI201130309T patent/SI2649070T1/en unknown
- 2011-12-05 EP EP11791543.9A patent/EP2649070B1/en active Active
- 2011-12-05 PL PL11791543T patent/PL2649070T3/en unknown
- 2011-12-05 PE PE2013001371A patent/PE20140226A1/en not_active Application Discontinuation
- 2011-12-05 AU AU2011340685A patent/AU2011340685A1/en not_active Abandoned
- 2011-12-05 PT PT117915439T patent/PT2649070E/en unknown
- 2011-12-05 AR ARP110104533A patent/AR084152A1/en unknown
- 2011-12-05 CA CA2816829A patent/CA2816829C/en active Active
- 2011-12-05 UA UAA201308329A patent/UA109037C2/en unknown
- 2011-12-05 MX MX2013006054A patent/MX2013006054A/en active IP Right Grant
- 2011-12-05 EA EA201390799A patent/EA022607B1/en not_active IP Right Cessation
-
2013
- 2013-04-25 IL IL225969A patent/IL225969A0/en unknown
- 2013-04-25 CO CO13105814A patent/CO6741154A2/en active IP Right Grant
- 2013-05-22 CR CR20130239A patent/CR20130239A/en unknown
- 2013-05-24 ZA ZA2013/03811A patent/ZA201303811B/en unknown
- 2013-06-04 CL CL2013001591A patent/CL2013001591A1/en unknown
- 2013-06-06 EC ECSP13012667 patent/ECSP13012667A/en unknown
- 2013-06-20 MA MA36027A patent/MA35086B1/en unknown
-
2014
- 2014-11-14 CY CY20141100951T patent/CY1115863T1/en unknown
- 2014-12-11 HR HRP20141200AT patent/HRP20141200T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012485A2 (en) | 2003-07-31 | 2005-02-10 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
WO2009152825A1 (en) * | 2008-06-20 | 2009-12-23 | H. Lundbeck A/S | Novel phenylimidazole derivatives as pde10a enzyme inhibitors |
Non-Patent Citations (25)
Title |
---|
A. HANZLOWSKY; B. JELENCIC; S. RECNIK; J. SVETE; A. GOLOBIC; B. STANOVNIK, J. HETEROCYCLIC CHEM., vol. 40, no. 3, 2003, pages 487 - 498 |
BEAVO, J., PHYSIOL. REV., vol. 75, 1995, pages 725 - 748 |
CONTI, M.; JIN, S.L., PROG. NUCLEIC ACID RES. MOL. BIOL., vol. 63, 1999, pages 1 - 38 |
COSKRAN T.M ET AL., J. HISTOCHEM. CYTOCHEM., vol. 54, no. 11, 2006, pages 1205 - 1213 |
FAWCETT, L. ET AL., PROCNATL ACAD SCI USA, vol. 97, no. 7, 2000, pages 3702 - 3707 |
FUJISHIGE K. ET AL., EUR J BIOCHEM, vol. 266, no. 3, 1999, pages 1118 - 1127 |
FUJISHIGE, K. ET AL., EUR. J. BIOCHEM., vol. 266, 1999, pages 1118 - 1127 |
FUJISHIGE, K. ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 18438 - 18445 |
GRAYBIEL, A.M., CURR. BIOL., vol. 10, 2000, pages R509 - R511 |
JAVITT DC ET AL., BIOL. PSYCHIATRY, vol. 45, 1999, pages 668 - 679 |
KEHLER J ET AL: "Patented PDE10A inhibitors: Novel compounds since 2007", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 19, no. 12, 1 December 2009 (2009-12-01), pages 1715 - 1725, XP002567797, ISSN: 1354-3776, DOI: 10.1517/13543770903431050 * |
LEWIS DA; LIEBERMAN JA, NEURON, vol. 28, 2000, pages 325 - 33 |
LOUGHNEY K. ET AL., GENE, vol. 234, no. 1, 1999, pages 109 - 117 |
MANALLACK, D.T. ET AL., J. MED.CHEM., vol. 48, no. 10, 2005, pages 3449 - 3462 |
NAKAZATO A; OKUYAMA S ET AL., EXP. OPIN. THER. PATENTS, vol. 10, no. 1, 2000, pages 75 - 98 |
RODEFER, J,S. ET AL., EUR. J. NEUROSCIENCE, vol. 2, 2005, pages 1070 - 1076 |
SANO, H., J. NEUROCHEM., vol. 105, 2008, pages 546 - 556 |
SEEGER, T.F. ET AL., BRAIN RES., vol. 985, 2003, pages 113 - 126 |
SHARMA T., BR.J. PSYCHIATRY, vol. 174, no. 28, 1999, pages 44 - 51 |
SIUCIAK, J.A. ET AL., NEUROPHARMACOLOGY, vol. 51, no. 2, 2006, pages 374 - 385 |
SIUCIAK, J.A. ET AL., NEUROPHARMACOLOGY, vol. 51, no. 2, 2006, pages 386 - 396 |
SODERLING S.H. ET AL., PROCNATL ACAD SCI USA, vol. 96, no. 12, 1999, pages 7071 - 7076 |
SODERLING, S.H.; BEAVO, J.A., CURR. OPIN. CELL BIOL., vol. 12, 2000, pages 174 - 179 |
VANDENBERG RJ; AUBREY KR, EXP. OPIN. THER. TARGETS, vol. 5, no. 4, 2001, pages 507 - 518 |
VERHOEST P R ET AL: "Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H pyrazol-3- yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 52, no. 16, 27 August 2009 (2009-08-27), pages 5188 - 5196, XP002567796, ISSN: 0022-2623, [retrieved on 20090724], DOI: 10.1021/JM900521K * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2757883A1 (en) * | 2011-09-22 | 2014-07-30 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
US9567333B2 (en) | 2011-09-22 | 2017-02-14 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
US9518055B2 (en) | 2011-09-22 | 2016-12-13 | Merck Sharp & Dohme | Imidazopyridyl compounds as aldosterone synthase inhibitors |
US9193724B2 (en) | 2011-09-22 | 2015-11-24 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
EP2757883A4 (en) * | 2011-09-22 | 2015-04-08 | Merck Sharp & Dohme | Triazolopyridyl compounds as aldosterone synthase inhibitors |
WO2013117610A1 (en) * | 2012-02-09 | 2013-08-15 | F. Hoffmann-La Roche Ag | Process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives |
US9115130B2 (en) | 2012-02-09 | 2015-08-25 | Hoffmann-La Roche Inc. | Process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives |
CN104955825A (en) * | 2013-01-31 | 2015-09-30 | 霍夫曼-拉罗奇有限公司 | Radiolabeled compounds |
WO2014118039A1 (en) | 2013-01-31 | 2014-08-07 | F. Hoffmann-La Roche Ag | Radiolabeled compounds |
US9777000B2 (en) | 2013-02-27 | 2017-10-03 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative |
KR20150120383A (en) | 2013-02-27 | 2015-10-27 | 모찌다 세이야쿠 가부시끼가이샤 | Novel pyrazole derivative |
US8980888B2 (en) | 2013-02-27 | 2015-03-17 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative |
WO2014133046A1 (en) | 2013-02-27 | 2014-09-04 | 持田製薬株式会社 | Novel pyrazole derivative |
CN107011343A (en) * | 2013-02-27 | 2017-08-04 | 持田制药株式会社 | Novel pyrazole derivative |
EP2963037A4 (en) * | 2013-02-27 | 2016-08-03 | Mochida Pharm Co Ltd | Novel pyrazole derivative |
US9440970B2 (en) | 2013-02-27 | 2016-09-13 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative |
US9453015B2 (en) | 2013-02-27 | 2016-09-27 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative |
US9458157B2 (en) | 2013-02-27 | 2016-10-04 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative |
RU2682247C2 (en) * | 2013-02-27 | 2019-03-18 | Мочида Фармасьютикал Ко., Лтд. | Novel pyrazole derivatives |
US8980889B2 (en) | 2013-02-27 | 2015-03-17 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative |
CN106957317A (en) * | 2013-02-27 | 2017-07-18 | 持田制药株式会社 | Novel pyrazole derivative |
CN106957317B (en) * | 2013-02-27 | 2019-12-31 | 持田制药株式会社 | Novel pyrazole derivatives |
RU2663834C2 (en) * | 2013-04-30 | 2018-08-10 | Ф. Хоффманн-Ля Рош Аг | Palladium-catalysed coupling of pyrazole amides |
CN105164126B (en) * | 2013-04-30 | 2017-05-31 | 豪夫迈·罗氏有限公司 | The Pd catalytic couplings of pyrazole amide |
WO2014177493A1 (en) | 2013-04-30 | 2014-11-06 | F. Hoffmann-La Roche Ag | Pd-CATALYZED COUPLING OF PYRAZOLE AMIDES |
US9505759B2 (en) | 2013-04-30 | 2016-11-29 | Hoffmann-La Roche Inc. | Pd-catalyzed coupling of pyrazole amides |
JP2016520047A (en) * | 2013-04-30 | 2016-07-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pd-catalyzed coupling of pyrazole amide |
CN105164126A (en) * | 2013-04-30 | 2015-12-16 | 豪夫迈·罗氏有限公司 | Pd-catalyzed coupling of pyrazole amides |
RU2681941C2 (en) * | 2013-05-31 | 2019-03-14 | Ниссан Кемикал Индастриз, Лтд. | Heterocyclic amide compound |
KR20170032329A (en) | 2014-07-30 | 2017-03-22 | 모찌다 세이야쿠 가부시끼가이샤 | Pyrazole derivative manufacturing method |
US9902723B2 (en) | 2014-07-30 | 2018-02-27 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
US10174025B2 (en) | 2014-07-30 | 2019-01-08 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
US9879009B2 (en) | 2014-07-30 | 2018-01-30 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
US20170210740A1 (en) * | 2014-07-30 | 2017-07-27 | Mochida Pharmaceutical Co., Ltd. | Pyrazole derivative manufacturing method |
KR20170032328A (en) | 2014-07-30 | 2017-03-22 | 모찌다 세이야쿠 가부시끼가이샤 | Pyrazole derivative manufacturing method |
WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
US11883385B2 (en) | 2020-06-05 | 2024-01-30 | Noema Pharma Ag | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2649070B1 (en) | Triazolopyridine compounds | |
CA2803156C (en) | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors | |
EP2552918B1 (en) | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors | |
KR101584925B1 (en) | Triazolopyridine compounds as pde10a inhibitors | |
EP2526098B1 (en) | Nitrogen-containing heteroaryl derivatives | |
EP2480546B1 (en) | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors | |
EP2604597B1 (en) | Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a | |
US9029536B2 (en) | Fused heterocyclic compounds | |
EP2602255A1 (en) | Fused heterocyclic ring compound | |
EP2687529A1 (en) | Condensed heterocyclic compound | |
AU2010299927B2 (en) | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors | |
TW201305155A (en) | Triazolopyridine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11791543 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011791543 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 225969 Country of ref document: IL Ref document number: 13105814 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2816829 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013500942 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2013-000239 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 2011340685 Country of ref document: AU Date of ref document: 20111205 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/006054 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013001591 Country of ref document: CL |
|
ENP | Entry into the national phase |
Ref document number: 2013542480 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001371-2013 Country of ref document: PE |
|
ENP | Entry into the national phase |
Ref document number: 20137016458 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201390799 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201308329 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2014/0574 Country of ref document: RS |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013013912 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013013912 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130605 |